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Abstract
Dihydrofolate reductase (DHFR) serves an important role in metabolism by
reducing dihydrofolate (DHF) to the product tetrahydrofolate via hydride transfer from
NADPH. R67 DHFR, a plasmid encoded form of the enzyme which provides resistance
to trimethoprim, functions as a homotetramer with D2 symmetry. Both ligands, DHF and
NADPH, interact within a 25Ǻ active site pore. Mutagenesis of one active site residue
results in four-symmetry related mutations causing large effects on binding and catalysis.
A construct containing four copies of the DNA for R67 DHFR ligated in-frame and
flanked by unique restriction sites was engineered and asymmetric mutants were built
using this construct. Q67H asymmetric mutants were built with the goal of preserving
tight binding without inhibition, as Q67H R67 DHFR binds both DHF and NADPH with
greater affinity than the wild-type enzyme, but also yields severe DHF and NADPH
inhibition [Park, H., Bradrick, T. D., and Howell, E. E. (1997) Protein Eng. 10, 14151424]. Although many of the Q67H asymmetric mutants bind NADPH with greater
affinity than the control, inhibition is often observed. From these studies, a role for Q67
in selecting for the productive ternary complex over inhibitory complexes was proposed.
Asymmetric Y69F mutants were also generated, as the kcat for Y69F R67 DHFR is
increased 2 fold compared to the wild-type enzyme, while the Km values are increased
[Strader, M. B., Smiley, R. D., Stinnett, L. G., VerBerkmoes, N. C., and Howell, E. E.
(2001) Biochemistry 40, 11344-11352]. These asymmetric mutants were constructed
with the goal of increasing kcat while maintaining high affinity. Although this goal was
not accomplished, these asymmetric mutants provided insight into ligand binding and
catalysis in R67 DHFR as they support a model where two Y69 residues interact with
iv

NADPH, while mutations along the dimer-dimer interface increasing kcat. Thus,
generating asymmetric mutants of R67 DHFR has provided a means by which to
understand ligand binding and catalysis in a homotetrameric enzyme where only a single
active site pore is available.
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Part I: A Background to R67 Dihydrofolate Reductase

1

Antibiotic Resistance and R-plasmid DHFRs
For several decades, drug companies have focused much attention on synthesis of
antibiotics which specifically target microbial cells (1). Antibiotics have been designed
to target several pathways in the microbial cell, ranging from pathways involved in
generation of the cell wall to pathways involved in metabolism of folate (2). Along with
the increase in use of the antibiotics came the realization that bacteria were able to
acquire resistance mechanisms which rendered the antibiotics ineffective (1). Although
several such resistance mechanisms have since been discovered, one particularly
interesting mechanism was identified in the 1970s in patients with bacterial infections
whose treatment involved use of the antibiotic trimethoprim (TMP) (3-7). In these
studies, chromosomal (bacterial) dihydrofolate reductase (DHFR), an enzyme involved in
folate metabolism, was the antibiotic target (3-7). Bacterial cells resistant to TMP were
found to contain an R-plasmid (or resistance plasmid) which afforded the resistance
mechanism. Interestingly, the R-plasmid contains the gene for a form of DHFR which
was not susceptible to TMP. Since the plasmid-encoded enzyme catalyzed the same
reaction as the chromosomal enzyme, bacterial cells were able to survive in the presence
of TMP even though their own DHFR was inhibited (5, 6).
Subsequent studies have determined that several distinct R-plasmid encoded
DHFRs exist. These R-plasmids have been categorized based on amino acid sequence
comparisons into 5 groups designated A-E. Of these five groups, one group, C, is
particularly interesting in that the amino acid sequences of members of this group are
rather dissimilar from those of the other groups ((8) and references therein). Group C
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consists of R-plasmid DHFRs classified as Type II DHFRs (8). Type II DHFRs are also
interesting from a clinical perspective due to their lack of sensitivity to TMP (9, 10).
One R-plasmid DHFR of particular interest in our laboratory is R67 DHFR. R67
DHFR is classified as a Type II R-plasmid encoded enzyme, distinguished along with
other Type II enzymes by its lack of sensitivity to TMP (9). Surprising to researchers at
the time of its discovery is that the enzyme shares no genetic homology with any
dihydrofolate reductases (10). Interestingly, studies also indicated that R67 DHFR exists
as a homotetramer (7).
DHFR: Metabolic Function
What functional role does DHFR play in metabolism? Dihydrofolate reductase
catalyzes the transfer of a hydride ion from the cofactor, NADPH, to the substrate, 7,8dihydrofolate, forming 5,6,7,8-tetrahydrofolate. This reaction is illustrated in Figure 1. It
plays an important role in single-carbon metabolism, a pathway important in generation
of purine nucleotides as well as other metabolites. As such, the enzyme’s function is
important to the survival of the cell. Thus, dihydrofolate reductases have been the target
of both antibiotic as well as anti-cancer drugs (11).
DHFR: Ligand Structures
Chemical structures for the ligands, NADPH and folate, are shown in Figure 2.
Both NADPH and NADH are composed of the following moieties: an adenine ring, two
ribose rings connected by a pyrophosphate bridge, and a nicotinamide ring. The
chemical reaction, or hydride transfer, occurs at the C4 (carbon four) position of the
nicotinamide ring. NADH and NADPH are distinguished by the presence of a phosphate
group at the 2′ position of the ribose ring (adjacent to the adenine ring) in NADPH that is
3
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Figure 1. Metabolic pathway involving dihydrofolate reductase. Modified from
(11).
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Figure 2. Chemical structures of ligands recognized by DHFR including folate and
NADPH. Taken from (12).
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not present in NADH. Instead, the ribose ring of NADH is unmodified, containing a
hydroxyl group at its 2′ position (11). DHF and folate are composed of a pteridine ring, a
para-aminobenzoic acid moiety (pABA), and a glutamic acid moiety (12). For both DHF
and folate, the chemical reaction occurs on the pteridine ring. DHF and folate are
distinguished by a reduction of folate’s C7-N8 (carbon seven-nitrogen 8) double bond
generating DHF. DHFR catalyzes the reduction of both folate to 7,8-DHF as well as the
reduction of 7,8-DHF to 5,6,7,8-tetrahydrofolate (11). However, in R67 DHFR, the
efficiency of the former is greatly reduced in comparison to the latter (Howell, personal
communication). For comparative purposes, the pyrophosphate-ribose-adenine moieties
of NADPH will be referred to as the NADPH tail while the ribose-nicotinamide moieties
will be referred to as the NADPH head. Similarly, the pteridine ring of DHF will be
referred to as the DHF head and the pABA-glutamic acid moieties will be referred to as
the pABA-glu tail (12).
R67 DHFR: Stereochemistry of Hydride Transfer
In oxidoreductase reactions, hydride transfer from NADPH or NADH to the
ligand is stereospecific. Dehydrogenases are often categorized as being either A-specific
or B-specific based on the stereochemistry of the transfer. A-specific dehydrogenases
catalyze the transfer of the pro-R hydrogen at carbon-4 of NADPH (or NADH) to the
ligand. In contrast, B-specific dehydrogenases catalyze the transfer of the pro-S
hydrogen at carbon-4 of NADPH (or NADH). The two classes of enzymes are also
distinguished in respect to the orientation of the cofactor within the active site. In Aspecific dehydrogenases, the ribonicotinamide bond is located in an orientation anti to the
carbon-3 amide substituent of the nicotinamide moiety. This orientation is syn for B6

specific dehydrogenases ((13) and references therein). For R67 DHFR, isotope studies
where the kinetics of hydride transfer are monitored when NADPD is substituted for
NADPH indicate that the pro-R hydrogen is transferred during the reaction (14, 15).
However, in contrast to other dehydrogenases, NMR studies suggest that the
ribonicotinamide bond is in a syn conformation in the active site (16).
R67 DHFR: Structure
The first crystal structure solved for the R67 DHFR was that of the dimer (17).
Chymotrypsin cleavage of the first 16 amino acids of each monomer (18) facilitated
crystallization of the active form of the enzyme, the homotetramer (19). This structure,
illustrated in Figure 3, indicates that R67 DHFR is a D2 symmetric enzyme possessing
222 symmetry. Structural evidence also indicates that the enzyme is a β-barrel protein
where each monomer is composed of five β-strands in an antiparallel orientation.
Assembly of each of the four monomers yields a 25Å pore that extends through the
center of the enzyme. Two pairs of symmetry-related glutamine 67 residues hydrogenbond generating a “floor” and “ceiling” to the pore (19).
R67 DHFR: Ligand Binding in the Active Site
In addition to the crystal structure for the apoenzyme, a crystal structure has also
been solved for an enzyme-folate complex. In this structure, the pteridine ring of one
folate molecule (designated FolI) interacts near the pore’s center such that its si face is
available for hydride transfer. A second folate molecule (designated FolII) binds further
out from the pore’s center in an orientation that prevents access to its si face for hydride
transfer. In contrast to the electron density observed for the pteridine rings for FolI and
FolII, diffuse electron density is observed for the pABA-glu tails of the two molecules.
7

Figure 3. Front view of R67 DHFR crystal structure (protein data bank 1VIE).
Monomers were originally labeled clockwise as ABDC and have been relabeled 1234,
where monomer 1 is green, monomer 2 is yellow, monomer 3 is magenta, and monomer
4 is cyan.
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This density orients the two pABA-glu tails in opposite directions away from the pore’s
center. The lack of a strong electron density for the tails suggests that the tails lack
specific contacts with the enzyme’s active site (19). These data are supported by docking
studies using the computer programs DOCK version 4.0 and SLIDE version 1.1 (12). In
these studies, the substrate, folate, was docked into the highest scoring enzyme·NMN
(nicotimamide mononucleotide) complex where the stereochemistry of hydride transfer
from NMN was A-side. (NMN contains the nicotinamide ring, ribose ring, and one
phosphate group of the NADPH pyrophosphate bridge.) In most high scoring predictions
using this software, FolI docked in an orientation similar to that observed in the crystal
structure. However, the docked location of the pABA-glu tail was not consistent within
the highest scoring conformers corresponding to the observed diffuse electron density in
the crystal structure. These data suggest that the pABA-glu tail displays some degree of
mobility within the active site (12, 19). Li et al. (16) propose that positive transferred
nuclear Overhauser interactions observed only for the glutamate tail of folate support
such a model.
In contrast to folate, no crystal structure has been determined for NADPH or an
NADPH moiety (such as NMN) bound to R67 DHFR. However, NMR studies have
provided some insight into NADPH binding in the active site of R67 DHFR. Although
no specific bonding interactions between the enzyme and cofactor were identified, shifts
in protein amide resonances upon cofactor (NADP+) binding implicate several amino
acids as being involved in ligand binding. Residues proposed by other studies to line the
active site (12, 19, 20) were most often associated with the greatest chemical shift
changes upon ligand binding (21).
9

R67 DHFR: Ligand Interactions in the Active Site
NMR studies have provided information regarding how the ligands bind within
the active site. In these studies, intraligand interactions are determined by transferred
nuclear Overhauser effects (NOE’s). Positive transferred NOE’s for the glutamic acid
tails of two folate molecules bound within the active site are observed. Interestingly, in
the same complex, negative tNOE’s for the pABA and pteridine moieties of folate are
noted. Combined, these data suggest that the tail mobile within the active site. In
contrast, transferred NOE studies suggest that NADPH binds where the bond between the
ribose and nicotinamide rings is syn while the bond between the ribose and adenine rings
is anti (16).
NMR studies have also revealed information regarding interactions between
NADPH and DHF, or interligand interactions, in the active site. These interactions are
distinguished by studies involving interligand Overhauser effects (ILOE’s) (16). Based
on the enzyme-folate complex determined by x-ray crystallography, Narayana et al. (19)
originally hypothesized that NADPH’s nicotinamide ring would interact between
glutamine 67 residues comprising the “ceiling” of the enzyme and FolI bound in close
proximity to the “floor” of the enzyme. Thus, both DHF and NADPH would bind in a
single half of the active site pore (16, 19). In such an orientation, strong interligand
interactions should occur between the pABA moiety of DHF and the nicotinamide ring of
NADPH. These interligand interactions were not observed by NMR studies suggesting
that such an arrangement of ligands within the active site is unlikely. In contrast, the
ILOE data suggest that the nicotinamide and pteridine rings bind near the pore’s center
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allowing the tail moieties of NADPH and DHF to project away from one another toward
opposite halves of the active site pore (16).
R67 DHFR: Stereochemistry of the Transition State
Quantum-mechanical/molecular-mechanical studies have been employed to
predict the orientation of the pteridine ring of DHF and the nicotinamide ring of NADPH
during catalysis. In vacuo studies suggest that two transition state stereochemistries are
possible, an endo transition state and an exo transition state (22). Of the two possible
transition states, an endo transition state yields the greatest overlap of the highest
occupied molecular orbitals and lowest unoccupied molecular orbitals (23). As a result,
the endo transition state is proposed to be 2-8 kcal/mole more stable than the exo
transition state (22). Addition of the active site environment to the calculations for E.
coli DHFR, however, suggests that in this enzyme catalyzed reaction, the exo transition
state is favored. Thus, active site interactions allow a transition state, less
thermodynamically favored in vacuo, to be approached in the enzyme active site (22). In
contrast to E. coli DHFR, ILOEs for a folate-NADP+-enzyme complex for R67 DHFR
support the use of an endo transition state for this enzyme (16).
R67 DHFR: No Proton Donor
Originally, it was proposed that an ionizable moiety is involved in the catalytic
mechanism for R67 DHFR as a non-linear pH versus rate profile was observed for the
enzyme. The pK associated with the pH versus velocity plot was determined to be 5.8
(18). It was therefore proposed that ionization of symmetry-related histidine 62 residues,
located along the dimer-dimer interface of R67 DHFR, may be involved in catalysis.
However, gel filtration studies indicated that at pH 5, the elution profile of the enzyme
11

represented that of a dimer, whereas at pH 8, the elution profile represented that of a
tetramer (24). In addition, steady-state kinetic analysis of dimeric H62C R67 DHFR
treated with DEPC indicated that the catalytic efficiency of the dimer is affected 200-600
fold. These studies indicate that the “bell-shape” nature of the pH versus activity plot is
therefore due to a disruption of the active tetrameric protein into a less active or inactive
dimeric protein at acidic pH values (around pH 6) (24).
What causes the > 100 fold increase in catalytic activity as pH is decreased from
~10 to ~7 in R67 DHFR (18)? Comparisons with E. coli DHFR led to the suggestion that
a proton donor other than histidine 62 may be involved in catalysis. In E. coli DHFR,
aspartic acid 27 is proposed to provide a proton to dihydrofolate during catalysis.
Mutagenesis studies where this residue is replaced with a serine result in a decrease in kcat
for the reaction (25).
Does R67, like E. coli DHFR, have a proton donor (26)? For R67 DHFR,
symmetry-related tyrosine 69 residues are the only amino acid residues with dissociable
side chains within the proposed active site that may provide a proton to DHF during
catalysis. However, pH versus rate profiles for R67 DHFR indicated that no ionization
effects are observed around pH 9.5-10, the solution pK of tyrosine (26). Titration of a
non-dissociable R67 DHFR mutant (H62C R67 DHFR) with acid yielded a linear pH
versus rate profile, where kcat increases as pH decreases. Based on these studies, it was
determined that, in contrast to E. coli DHFR, there is no proton donor in R67 DHFR, and
the substrate must be pre-protonated for the reaction to occur (26).
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R67 DHFR: Catalytic Mechanism
Prior to ligand binding and x-ray crystallography studies, it was proposed that due
to the symmetry of R67 DHFR, four ligands could potentially bind within the large active
site pore (27, 19). However, x-ray crystallography studies suggest that a total of two
folate molecules associate with the enzyme, where steric effects prevent four from
binding (19). In addition, ligand binding studies using isothermal titration calorimetry
and fluorescence anisotropy suggest that steric effects allow a limit of two ligands to bind
within the active site. This includes two non-productive complexes where two NADPH
or two DHF molecules interact with the enzyme. A single productive, ternary complex
forms when one NADPH and one DHF molecule interact in the active site (19).
In addition to the stoichiometric data obtained from these studies, isothermal
titration calorimetry studies also provided information regarding interaction between
ligands within the active site, in particular, their cooperative behavior (27). When the
binding of one ligand in the active site affects the binding of a second ligand within the
active site, the two ligands are said to be cooperative. Two types of cooperativity are
possible based on the nature of the interactions within the active site. If one molecule
binds in a manner that requires the second ligand to display a weaker affinity to the
enzyme, the interligand interaction is negatively cooperative. In contrast, if the binding
of the first ligand allows the second ligand to bind more tightly, the interaction is
positively cooperative. Cooperativity patterns between two ligands can be determined by
dividing the dissociation constant for the second ligand binding event by the dissociation
constant for the first ligand binding event (i.e. Kd2/Kd1) (20, 27). When the Kd2/Kd1 value
is greater than one, the pattern reflects positive cooperativity. However, when the value
13

is less than one, the pattern of ligand binding suggests negative cooperativity. If no interligand cooperativity occurs (i.e. the ligands bind independently of one another), a value
of one is expected (20, 27).
Comparison of the Kd values for the first and second NADPH binding events in
R67 DHFR yielded a Kd2/Kd1 value less than one, suggesting that the two NADPH
molecules interact in a negatively cooperative fashion within the active site (27). To
explain this pattern of cooperativity, it was suggested that the first NADPH molecule
interacts with the enzyme close to the pore’s center. This binding was proposed to
prevent tight binding of a second NADPH molecule in a symmetry related site through
steric or electrostatic interactions. In contrast, comparisons of the binding affinities for
two DHF/folate molecules within the active site indicated that these ligands display
positive cooperativity. It was therefore suggested that the first DHF/folate molecule
binds with weak affinity within the active site. However, the second DHF molecule
interacts with both the enzyme and the already bound DHF/folate molecule resulting in
an increased binding affinity. In addition, interactions are also proposed to occur
between NADPH and DHF, bound in the productive, ternary complex. Specifically, it is
proposed that positive cooperativity occurs between NADPH and DHF that allows DHF
to bind with a greater affinity in the productive complex (27). These studies, in addition
to steady-state kinetic studies for wild-type R67 DHFR (18), have allowed a mechanism
for catalysis to be proposed. A diagram of this mechanism is shown in Figure 4. Based
on these studies, it is proposed that R67 DHFR can follow a random bi-substrate
mechanism, but favors a pathway where NADPH interacts with the enzyme first followed
by DHF (based on the Kd values and cooperativity patterns). Cooperativity patterns
14
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Figure 4. Proposed binding scheme for R67 DHFR. Double arrows represent events in
equilibrium while the single arrow represents the rate-determining step for the enzyme
catalyzed reaction. Taken from (27).
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between two bound NADPH molecules and two bound DHF molecules disfavor their
formation in comparison to the active ternary complex. Thus, substrate and cofactor
inhibition are not detected for R67 DHFR (18, 27). Kinetic isotope studies using
NADPD also show an isotope effect of 3 indicating that the hydride transfer step is ratelimiting (14).
R67 DHFR: Inhibitor Studies
In order to better understand the mechanism of R67 DHFR, inhibition studies
were performed. In these studies, no inhibition by DHF or NADPH was detected while
only minor inhibition by tetrahydrofolate was detected. The substrate, folate, displayed
competitive inhibition with respect to DHF and noncompetitive inhibition with respect to
NADPH. NADP+ was competitive with respect to NADPH and para-uncompetitive with
respect to DHF. Based on these inhibitor studies as well as isotope effects indicating that
hydride transfer is the rate-limiting step for the reaction, it was proposed by Morrison and
Sneddon that R67 DHFR follows a “Bi-Bi rapid equilibrium, random mechanism” (15).
R67 DHFR: Residues Comprising the Active Site Pore
Docking studies predict that several residues near the active site pore may be
involved in binding DHF and/or NADPH. These include lysine 32, serine 65, valine 66,
glutamine 67, isoleucine 68, and tyrosine 69 (12). The crystal structure for R67 DHFR
where the active site residues are highlighted is shown in Figure 5. The proposed
contacts between the active site residues and specific moieties of the substrate and
cofactor based on docking predictions are illustrated in Figure 6. In attempts to better
understand how these active site residues are involved in ligand binding and catalysis,
site-directed mutagenesis studies have been performed, and the mutants have been
16

A

B

C
Figure 5. Conolly surface map of R67 DHFR. Active site residues affecting ligand
binding and/or catalysis are highlighted in blue. Residues in green have minimal affects
on ligand binding and catalysis, while magneta residues are important for dimer-dimer
interactions. Panel A shows a front view of the Conolly surface map. Panel B shows a
view of a single dimer interface generated by dissecting the tetramer in half along the
dimer-dimer interface. Panel C is a view of a single monomer interface generated by
dissecting the tetramer in half along the monomer-monomer interface. Taken from (30).
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Figure 6. Proposed contacts between R67 DHFR active site residues and ligands.
Taken from (12).
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characterized (20, 28, 29). For clarity, the proposed interactions for each of these
residues will be described followed by the effects of mutagenesis on ligand binding and
catalysis.
Lysine 32
Docking studies suggest that lysine 32 may provide contacts to the glutamate
moiety of DHF. In addition, these studies indicate that a symmetry-related lysine 32 may
also provide binding contacts to the 2′ phosphate moiety of the cofactor (12). Lysine 32
was therefore mutated to methionine. However, K32M R67 DHFR was unable to be
characterized kinetically and thermodynamically since the mutations resulted in a dimer
(28). This residue will be considered later as the electrostatic potential of the enzyme is
discussed.
Serine 65
No direct interactions are predicted between serine 65 and either NADPH or
DHF. However, docking studies do predict that the –OH group of serine 65 may interact
via a water mediated hydrogen bond with a ribose hydroxyl group and with a phosphate
oxygen of NMN (12, 20). No specific interactions between serine 65 and folate were
predicted by docking studies. However, since the hydroxyl group of the residue is
directed toward the active site, a potential role in hydrogen bonding interactions with the
ligand was also proposed (12, 20). Serine 65 was mutated to alanine residue to remove
its potential for hydrogen bond formation through its side chain. S65A displayed similar
kinetic and thermodynamic characteristics to that of the wild-type enzyme. These data
suggest that either the serine hydroxyl group is not involved in binding DHF and NADPH
or that the interactions are not direct (12, 20).
19

Glutamine 67
Symmetry-related glutamine 67 residues are proposed to play an important role in
definition of the active site architecture as x-ray crystallographic data indicate that they
contribute the “floor” and “ceiling” to the active site (19). Docking studies also indicate
that these residues play an important role in binding interactions with both NADPH and
DHF. Specifically, it is proposed that hydrogen bonding interactions between a
glutamine 67 side chain and a ribose hydroxyl group of NMN occur. In addition, it is
predicted that van der Waals contacts between glutamine 67 and the nicotinamide moiety
of NMN occur. Similar interactions are proposed between symmetry-related glutamine
67 residues and the folate’s pteridine ring (12, 20). Symmetry-related glutamine 67
residues were mutated to histidine residues to generate Q67H R67 DHFR (29) and to
cysteine residues to generate Q67C R67 DHFR (20). These mutations both resulted in a
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slower kcat for the reaction. However, the two mutations had opposite effects on Km(DHF)
and Km(NADPH). For Q67H R67 DHFR, Km(DHF) is ~ 25 fold tighter than the wild-type
value while the Km(NADPH) is ~ 100 fold tighter than R67 DHFR. In contrast, the Km(DHF)
for Q67C R67 DHFR increased ~ 9.5 fold while the Km(NADPH) increased ~ 9 fold. These
studies suggest that symmetry-related glutamine 67 residues play a role in binding
NADPH and DHF (12, 20, 29).
Isoleucine 68
Docking studies predict that backbone amide and carboxyl moieties of isoleucine
68 interact with the nicotinamide ring of NMN while van der Waals contacts are also
predicted between the residue and NMN. In addition, the backbone amide of I68 is also
predicted to interact via a hydrogen bond with the pteridine ring of folate. A water
20

mediated interaction between the backbone amide of another isoleucine 68 and the
pteridine ring of folate is proposed as well (12, 20). Therefore, symmetry-related I68
residues were mutated in two different experiments to leucine and methionine generating
I68L R67 DHFR and I68M R67 DHFR, respectively (20). In both mutants, the Km(DHF)
values were increased ~ 4 fold while the Km(NADPH) values were increased ~ 7-9 fold.
Both mutations also resulted in a decrease in kcat for the reaction, with the I68M mutant
having the most dramatic effect. Ligand binding studies were also conducted for I68L
R67 DHFR to determine the effects of the mutations on binding of NADPH to the
enzyme using isothermal titration calorimetry. In these studies, the binding of the first
NADPH is increased ~ 10 fold while the binding of the second NADPH is increased ~ 5
fold. These data suggest that symmetry-related I68 residues comprise the binding sites
for both NADPH and DHF (12, 20).
Tyrosine 69
Docking studies predict formation of two types of interactions between Y69 and
NMN. These include a water mediated hydrogen bond between the hydroxyl of the
residue and a phosphate oxygen of NMN as well as van der Waals contacts between the
ring edge of the residue and ribose hydroxyl groups of NMN. A possible interaction
between tyrosine 69 and folate has also been proposed from docking studies.
Specifically, a hydrogen bonding interaction is predicted between the hydroxyl of the
amino acid and the glutamate tail of the ligand (12, 20). Thus, symmetry-related Y69
residues were mutated to either phenylalanine residues to generate Y69F R67 DHFR or
to histidine residues to generate Y69H R67 DHFR (20). Both mutations increased the
Km(DHF) to a similar extent, ~ 8 fold. However, the histidine mutations had a more
21

dramatic effect on the Km(NADPH) value, with a value ~ 59 fold greater than the wild-type
enzyme versus the 22 fold greater value observed for Y69F R67 DHFR. Interestingly,
the effects on kcat were also unique. For Y69F R67 DHFR, the kcat was increased > 2 fold
while the reaction rate for Y69H R67 DHFR was ~ 100 fold slower than the wild-type
enzyme. Again, these data suggest that Y69 residues comprise a portion of the binding
sites for both DHF and NADPH (12, 20).
R67 DHFR: “Hot Spot” Binding
Site-directed mutagenesis studies of homotetrameric R67 DHFR as well as
docking studies suggest that R67 DHFR may display a “hot spot” binding mode (12, 20).
“Hot spot” or “consensus” binding modes are often observed in proteins which recognize
more that one unique ligand or “partner” (31). For example, immunoglobulin G (IgG)
recognizes several unique protein scaffolds. Comparing the interactions between IgG and
each of the protein partners reveals that several IgG residues are involved in interactions
with each of the scaffolds. In particular, a surface is formed by those residues commonly
involved in the interactions. In the IgG surface, the residues comprising the surface have
a large degree of hydrophobicity (31). However, other “hot spots” are recognized by
their amphipathic character (12, 20). Such is the case for R67 DHFR. In this enzyme,
several of the residues proposed to comprise the active site also display some
amphipathic character. For example, the side chain of tyrosine 69 is composed of a
hydrophobic ring as well as a polar hydroxyl group. Although the R-chains of valine 66
and isoleucine 68 are non-polar, their amide and carbonyl backbone moieties provide
polar character since they are also appropriately positioned for interactions with the
ligands. In addition, the symmetry of R67 DHFR is important for this “hot spot” binding
22

mode as docking studies indicate that symmetry related residues may play a role in
binding both ligands. These studies also suggest that the binding sites for the two ligands
share some degree of overlap. Based on these characteristics, R67 DHFR is proposed to
have a “hot spot” binding mode (12).
R67 DHFR: Electrostatic Interactions
An electrostatic potential map for R67 DHFR was constructed with the program,
DELPHI. These studies indicate that the active site of R67 DHFR is positively charged
(12). Since both NADPH and DHF are negatively charged, it was suggested the positive
charge character of the enzyme draws the ligands towards the active site (12, 28). A
large portion of the positive potential is generated by two adjacent residues, lysine 32 and
lysine 33. In addition to generating a positive electrostatic potential, docking studies also
suggest that symmetry-related lysine 32 residues facilitate binding of both DHF and
NADPH by participating in electrostatic contacts (12). In order to assess the involvement
lysine 32 in ligand binding and catalysis, this residue was mutated to both polar and
nonpolar residues. Unfortunately, each of the cells expressing these mutants was TMP
sensitive. K32A and K32M were further characterized and both decreased the stability of
the tetramer resulting in inactive dimers. Studies involving K33M indicate that it is
active and tetrameric. In fact, this mutant is similar to wild-type R67 DHFR both
kinetically and thermodynamically. It was therefore proposed that this residue
contributes only weakly to ligand binding and catalysis (28).
To indirectly address the role of K32 residues in ligand binding and catalysis, salt
studies were performed on R67 DHFR as well as the K33M mutant. In these studies,
increasing concentrations of salt in the buffer medium should interfere with ionic contacts
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formed between K32 and the ligands. In these experiments, Km values for both ligands
increased linearly as the amount of salt in the buffer was increased. The same trend was
observed for the kcat for the reaction. In addition, ligand binding for both folate and
NADPH was affected by increasing salt concentrations. Based on these studies, it was
suggested that K32 forms contacts with the pyrophosphate bridge and 2′ phosphate of
NADPH. In addition, these studies indicate that an ionic interaction must be disrupted in
order to approach the transition state for the reaction (28).
R67 DHFR: Other Catalytic Functions
In addition to catalyzing the reduction of DHF to tetrahydrofolate, NMR studies
suggest that R67 DHFR may catalyze two other reactions. One alternate activity of R67
DHFR is that of a phosphatase. Specifically, it has been indicated that R67 DHFR
catalyzes the conversion of NADP+ to NAD+ over time. This side reaction is however
slow (on the order of hours) compared to the catalytic activity of other enzymes (21).
In addition to its phosphatase activity, NMR studies also indicate the ability of
R67 DHFR to catalyze a transhydrogenase reaction. This reactivity stems from the
enzyme’s ability to bind NADPH and NADP+ simultaneously in a non-productive
complex (in respect to the enzyme’s dehydrogenase activity). These studies indicate that
the enzyme is able to facilitate the transfer of a hydride from the reduced cofactor to the
oxidized cofactor to an extent (21).
R67 DHFR: Generation of the Quad Construct
Since R67 DHFR is a tetramer formed by the interaction of four identical
monomers, site-directed mutagenesis of the gene coding for the monomer results in four
symmetry-related mutations in the tetramer. This often has large effects on both ligand
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binding and catalysis. Specifically, binding affinities of both DHF and NADPH are often
both affected by the mutations (20, 28). Bradrick et al. (27) approached this problem by
generating the Quad 1 construct which contains four copies of the DNA for the monomer
associated in-frame. A schematic of this construct is shown in Figure 7. The linker
region between each of the gene copies is the DNA coding for the first 17 amino acids of
the monomer (32). These residues are not ordered in the crystal structure for the dimeric
enzyme and were cleaved facilitating crystallization of the tetramer (17, 19). In addition,
chymotrypsin cleavage of the first 16 residues does not alter enzyme activity (18). Quad
1 was characterized and compared to wild-type R67 DHFR to ensure that linking the
genes had not affected protein structure and/or enzyme activity. Steady-state kinetic
parameters for the two enzymes were similar suggesting that linking the genes had not
affected enzyme activity. In contrast to wild-type R67 DHFR, Quad 1 was unable to
regain full activity upon refolding following unfolding with guanidine hydrochloride at
pH 8. Quad 1, since it is monomeric, is also unable to dissociate into dimers following
titration with hydrochloric acid. However, titration can cause the subunits of the
monomer to “splay out” as symmetry-related histidine 62 residues are protonated.
Interestingly, these titrations yield a pKa value for symmetry-related histidine 62 residues
in Quad 1 which is decreased (~ 5.5) with respect to that for R67 DHFR (~ 6.8).
Although these differences between Quad 1 and R67 DHFR were noted, Quad 1 was still
considered a good mimic of the homotetrameric enzyme (32).
One concern regarding Quad 1 was that of its final topology. In these studies, it
was predicted that several different topologies were possible for the enzyme. However,
in only two of the topologies (ABCD and ABDC) does a linker span the dimer-dimer
25

Quad 1
Gene Copy 1

Gene Copy 2

Gene Copy 3

Gene Copy 4

Start M1………….. S59………. I77-N78-M1…………. I77-N78-M1..….….. I77-N78-M1…....H62…… N78 end
ATG-ATC-AAG…TCT.. ATC-AAC-ATG…….. ATC-AAC-ATG….. ATC-AAC-ATG……..CAC….. AAC-TAA-TAGBcl1
EcoR1

Quad 2
Gene Copy 1

Gene Copy 2

Gene Copy 3

Gene Copy 4

Start M1………… S59………. I77-N78-M1…………. I77-N78-M1..….….. I77-N78-M1…...H62... N78 end
ATG-ATC-AAG…TCT…ATC-GAT-ATC……..AGG-TAC-CTC….. AGG-GCC-CTG….CAC… AAC-TAA-TAGBcl1

EcoRV

KpnI

Quad 3
Gene Copy 1

Gene Copy 2

ApaI
Gene Copy 3

EcoR1
Gene Copy 4

Start M1………… S59A……. I77-N78-M1…………. I77-N78-M1..….….. I77-N78-M1…...H62L… N78 end
ATG-ATC-AAG…GCT.…. ATC-GAT-ATC……..AGG-TAC-CTC….. AGG-GCC-CTG….CTC… AAC-TAA-TAGBcl1
ApaI
EcoRI
EcoRV
KpnI
Figure 7. Comparison of Quad gene constructs of R67 DHFR. The gene copy number is listed above the amino acid
sequence which is above the nucleotide sequence. Each gene copy corresponds to a monomer of R67 DHFR. Quad 1
contains the DNA encoding the monomers associated in-frame while Quad 2 incorporates unique restriction enzyme sites
which are highlighted. Quad 3 contains a S59A and H62L mutation in domains 1 and 4, respectively. Modified from (33).
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interface a single time. Of these two topologies, the ABCD topology requires the shortest
span of the linker region across the dimer-dimer interface suggesting that this topology
may be favored (32). A schematic of this is shown in Figure 8 where monomers ABCD
are renamed as domains 1234 (33).
Quad 1 was originally constructed as a first step in the goal of generating
asymmetric mutation. Since each gene, linked in-frame in Quad 1, is identical, primers
designed for site-directed mutagenesis studies recognize the same region in every gene.
Unfortunately, this approach yields four symmetry-related mutations. As a solution to
this problem, a new construct was generated. This construct, named Quad 2, is shown in
Figure 7. Quad 2 is similar to Quad 1 in that it also contains four copies of the DNA for
the R67 DHFR monomer associated in-frame. Again, the linker region between the
genes is the DNA coding for the first 17 amino acids of the monomer. However, each of
the genes is flanked by unique restriction enzyme sites. In addition to the Quad 2
construct, four additional constructs were generated. These constructs contain a single
copy of the gene flanked by unique restriction enzyme sites. An asymmetric mutation
can be generated by performing site-directed mutagenesis on one of the single copy
genes. The plasmid containing the gene is then digested by the appropriate restriction
enzymes. At the same time, Quad 2 is also digested with the same restriction enzymes.
The single gene copy containing the appropriate mutation is then ligated into the Quad 2
construct (33, Hicks et al., manuscript in preparation).
Asymmetric mutations of glutamine 67 residues were generated using this system.
Two of these mutants were characterized kinetically: Q67H: 1+3 and Q67H: 1+4.
Before proceeding, it is necessary to explain the nomenclature that will be used to
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Figure 8. Schematic of "topology switching" phenomenon. Panel A illustrates the
equilibrium proposed between the two topologies of the Quad 2 protein. Panel B shows
the shift in equilibrium proposed to occur upon introduction of a S59A mutation in
domain 1 and an H62L mutation in domain 4.
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describe the asymmetric mutants throughout this dissertation. We will identify the wildtype residue and its position in the monomeric amino acid sequence first. This will be
followed by the single letter code for the residue to which it is being mutated. We will
then identify the asymmetric location of the mutations. As shown in Figure 3, we have
identified each domain of the monomeric Quad 2 construct numerically where domain 1
occurs in the bottom-left region and the numbering continues in a clock-wise manner.
Therefore, Q67H: 1+3 contains two glutamine 67 residues mutated to histidine residues.
The Q67H mutations are located in domain 1 and in domain 3. Six unique asymmetric
mutants can be generated using this system, one single mutant, three double mutants, one
triple mutant, and one quadruple mutant. These are: Q67H: 1, Q67H 1+2, Q67H: 1+3,
Q67H: 1+4, Q67H: 1+2+3, and Q67H: 1+2+3+4. A schematic of these asymmetric
mutations is shown in Figure 9 (33). The same pattern of asymmetric mutations applies
regardless of the residue mutated.
Originally, it was proposed that by generating asymmetric mutations, it might be
possible to provide unique binding sites for NADPH and DHF (27, 29). In addition, it
was proposed that each asymmetric mutant would be unique since each mutant would
provide a slightly different active site to the ligands. Therefore, it was proposed that the
kinetic properties of Q67H: 1+3 and Q67H: 1+4 would be different. However, initial
steady- state kinetic evaluation of the mutants indicated that the two were similar
kinetically. This led to the conclusion that the Quad constructs may not exist in a single
topology. Instead, it was suggested that a “topology-switching” phenomenon may occur.
If this topology-switching does occur, Q67H: 1+3 and Q67H: 1+4 are no longer unique
(33). This is illustrated in Figure 8.
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Figure 9. Schematic of unique Q67H asymmetric mutants. Each sphere represents a
domain of Quad 3 where each domain is numbered clockwise. One unique single
mutant (Q67H: 1), three unique double mutants (Q67H: 1+2, Q67H: 1+3, and Q67H:
1+4), one unique triple mutant (Q67H: 1+2+3), and one unique quadruple mutant
(Q67H: 1+2+3+4) are possible using the Quad 3 construct. Modified from (33).
30

Studies by Dam et al. (34) provided a solution to the “topology-switching”
problem. These researchers generated several mutations at serine 59 and histidine 62 in
homotetrameric R67 DHFR. These two residues were considered important as they form
a hydrogen bond that is lost upon protonation of histidine 62 (19, 24). Protonation of
symmetry-related 62 residues causes the homotetramer to dissociate resulting in dimers
(24). Mutation of symmetry-related serine 59 residues to alanine residues yielded dimers
that were unable to self-associate as did mutation of symmetry-related histidine 62
residues to leucine residues. Interestingly, combining these dimeric mutants in a 1:1 ratio
generated a heterotetramer with kinetic characteristics similar to that of the wild-type
protein (33, 34).
Based on the findings of Dam et al. (34), a final Quad construct was generated,
Quad 3. The Quad 3 construct is shown in Figure 7. Quad 3 is a modified version of
Quad 2 which contains two additional mutations: a S59A mutation in domain 1 and a
H62L mutation in domain 4. The Quad 3 construct was used to generate each of the
asymmetric mutations described in this dissertation. Characterization of Q67H
asymmetric mutants generated in the Quad 3 construct suggest that a shift in the
equilibrium towards a single topology occurs in this construct as illustrated in Figure 8.
Goal of Research Project
The goal of this research project is to asymmetrically mutate R67 DHFR such that
unique binding sites are provided to the substrate and cofactor. By doing so, we propose
to gain an understanding of the contacts occurring between residues located in specific
domains of the active site and the ligands. For this project, we have chosen to focus on
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two active site residues, glutamine 67 and tyrosine 69, both of which are proposed to
interact with both DHF and NADPH.
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Abstract
R67 dihydrofolate reductase (DHFR) is an R-plasmid encoded enzyme that
confers resistance to the antibacterial agent, trimethoprim. This homotetramer possesses
a single active site pore and exact 222 symmetry. The symmetry imposes constraints on
the ability of the enzyme to optimize binding of the substrate, dihydrofolate (DHF), and
the cofactor, NADPH, resulting in a “one site fits both ligands” approach. This approach
allows formation of either a NADPH•NADPH, a dihydrofolate•dihydrofolate or a
NADPH •dihydrofolate complex. The first two complexes are non-productive while the
third is the productive catalytic species. To break the symmetry of the active site, a
tandem array of four R67 DHFR genes has been linked in frame, allowing individual
manipulation of each gene copy. Various numbers and combinations of asymmetric
Q67H mutations have been engineered into the tandem gene array. The Q67H mutation
was chosen for investigation as it was previously found to tighten binding to both
dihydrofolate and NADPH by ~ 100 fold in homotetrameric R67 DHFR (1). Nonadditive effects on ligand binding are observed when 1 to 4 mutations are inserted,
indicating either conformational changes in the protein or different cooperativity patterns
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in the ligand•ligand interactions. From steady state kinetics, addition of Q67H mutations
does not drastically affect formation of the NADPH•dihydrofolate complex, however a
large energy difference between the productive and non-productive complexes is no
longer maintained. A role for Q67 in discriminating between these various states is
proposed. Since theories of protein evolution suggest gene duplication followed by
accumulation of mutations can lead to divergence of activity, this study is a first step
towards asking if introduction of asymmetric mutations in the quadruplicated R67 DHFR
gene can lead to optimization of ligand binding sites.
Introduction
Dihydrofolate reductase (DHFR)1 reduces dihydrofolate (DHF) to tetrahydrofolate using the cofactor NADPH in a hydride transfer reaction. Tetrahydrofolate is
essential for cell survival as it is a precursor for formation of thymidylate, methionine,
purine nucleosides, as well as other intermediates in metabolism. The antibiotic
trimethoprim has been used clinically as an inhibitor against E. coli chromosomal DHFR.
However, R-plasmid encoded R67 DHFR confers resistance to this antibiotic. This
DHFR variant is not homologous either in genetic composition or structure to the
chromosomally encoded enzyme (2,3).

1

Abbreviations: DHFR, dihydrofolate reductase; wt, wild type; TMP, trimethoprim; DHF,
dihydrofolate, NADP(+/H), nicotinamide adenine dinucleotide phosphate (oxidized/reduced);
NMNH, reduced nicotinamide mononucleotide; MTH buffer, 50 mM MES + 100 mM Tris, +
50 mM acetic acid polybuffer; ITC, isothermal titration calorimetry; CD, circular dichroism.
Mutant enzymes containing amino acid substitutions are described by the wild type residue
and numbered position in the sequence, followed by the amino acid substitution. For
example, Q67H R67 DHFR describes the gln67 → his mutant.
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Numerous observations lead to the hypothesis that R67 DHFR is a primitive
enzyme. First, the active species is a homotetramer that possesses 222 symmetry as
shown in Figure 1 (protein data bank file 1VIE, ref 3). The single active site is a 25 Å
pore that extends the length of the protein. As a consequence of the 222 symmetry,
binding of DHF and NADPH to the pore results in formation of three different complexes
(DHF•DHF, NADPH•NADPH or DHF•NADPH; ref 4). Only the ternary complex
(DHF•NADPH) results in catalysis. For the latter complex, DHF occupies half the pore
and cofactor the other half; the pteridine ring of DHF and the nicotinamide ring of
NADPH encounter each other at the center of the pore where the reaction occurs (5). A
drawback of the 222 symmetry is that binding to NADPH and DHF cannot be
independently optimized. The enzyme appears to possess a binding “hot spot” that can
accommodate (with some degree of overlap) both DHF and NADPH (6,7).
A second observation suggesting R67 DHFR is a primitive enzyme is that
mutations typically have a large cumulative effect since one mutation per gene results in
four mutations per active site. Mutations that tighten binding do not necessarily lead to
enhanced catalytic efficiency as binding is concurrently tightened in all symmetry related
sites. This leads to substantial substrate and cofactor inhibition because of formation of
the nonproductive complexes, DHF•DHF and NADPH•NADPH (1,4).
A third observation is that R67 DHFR does not possess a general acid in its active
site pore. Instead it requires the substrate be activated by protonation (1,8-9). In other
words, catalysis increases as the pH approaches the pKa of N5 on DHF (2.59; ref 10).
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Introduction of asymmetric mutations should break the constraints imposed on
R67 DHFR due to its 222 symmetry, leading to addition of functional groups or building
substrate specificity. For the latter, mutations may be added to one half the pore leading
to more specific binding of NADPH. Conversely, specificity may be built in the other
half of the pore, allowing more precise binding of DHF. Construction of asymmetric
mutations by mixing populations (e.g. wildtype and mutant R67 DHFRs) is limited by the
pH dependent dissociation of tetrameric R67 DHFR into dimers (11). Thus any
heterotetramers formed and isolated will readily dissociate and reassociate to a mixture of
homo- and heterotetramers upon titration of His62 and its symmetry related residues2 at
pH values ≤8.
To construct asymmetric mutations in R67 DHFR, a gene oligomerization
strategy is necessary. Therefore, Bradrick et al. (12) linked in-frame four copies of the
gene coding for the 78 amino acid monomer. The protein product of this tandem gene
array is an active monomer with four times the mass of the wildtype (wt) monomer and
that possesses the essential tertiary structure of the wt homotetramer. The linker between
gene copies corresponds to the natural N-terminus. In this protein, residues are not
numbered consecutively. Instead residues 1-78 describe the 1st (A) domain, residues 101178 describe the 2nd (B) domain, residues 201-278, the 3rd (C) domain and residues 301378, the 4th (D) domain. The domains correspond to the monomers in wt R67 DHFR.
2

The amino acids in the first monomer (A) are labeled 1-78; those in the second
monomer (B), 101-178; those in the third monomer (C), 201-278; and those in the fourth
monomer (D), 301-378. For brevity, when a single residue is mentioned, all four
symmetry related residues are implied. The monomer arrangement going clockwise in
the crystal structure 1VIF is ABDC (3). To minimize confusion in the quadruplicated
gene construct, we have re-labeled the monomers ABCD going clockwise.
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This paper describes the addition of asymmetric mutations to the tandem gene
array. The Q67H substitution was initially chosen for analysis as it tightens binding to
both NADPH and DHF in the context of the wt homotetramer (1). Glutamine 67 and its
symmetry related residues occur at the center of the active site pore. They form the
“ceiling” and “floor” of the pore (Figure 1). Each Q67 residue hydrogen bonds with a
symmetry related Q67 residue at both dimer-dimer interfaces. Both of the hydrogenbonded pairs extend into the active site causing the pore radius to decrease near the
middle. From the folate co-crystal structure, Q67 forms extensive van der Waals
interactions with the pteridine ring of folate (3). Our recent computational docking
studies using DOCK (docking based on van der Waals interactions) and SLIDE (docking
based on hydrogen bond formation) predict interactions between Q67 and NMNH
(reduced nicotinamide-ribose-Pi moiety of NADPH) (6). In these predicted interactions,
Q67 may form a hydrogen bond to one of the ribose OHs (O2′) through its NE2 group as
well as form van der Waals interactions with several atoms of the nicotinamide ring
through its sidechain. This ternary complex model proposes that Q67 serves a dual role
in binding both folate/DHF and NADPH. The previously constructed Q67H mutant also
supports this notion as it tightens binding to both NADPH and DHF by factors of 100 and
6000 fold respectively (1). Binding affinity may be strengthened due to ring stacking
interactions between the imidazole ring of histidine and the nicotinamide and/or pteridine
rings of NADPH and DHF respectively (13-15).
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Figure 1. Top left: the ribbon structure of homotetrameric R67 DHFR (1VIE in the
protein data bank). Each monomer is shaded differently and labeled A, B, C or D.
While 1VIE assigns the monomer topology as ABDC going clockwise, we have
revised this to ABCD to minimize confusion in the four gene copy construct. The
single active site pore occurs in the center of the structure. The Q67 sidechains are
highlighted; they appear at the top and bottom surfaces of the active site pore. Top
right: An enlarged view of a pair of symmetry related Q67 residues from the B and C
subunits. The Q67s are in the center of the image in ball and stick format and the NE2
and OE1 atoms labeled. Water molecules are given as stars. The active site pore is
directly below the 2 glutamines. The rest of the figure: a cartoon representing the
topologies of various asymmetric Q67H mutations. Quad 3 is the parent structure that
possesses covalent linkers between each monomer in homotetrameric (wt) R67 DHFR.
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Materials and Methods
Site-directed mutagenesis
A synthetic R67 DHFR gene, carried in pUC8, has been previously described
(16). A tandem array of 4 R67 DHFR genes was previously constructed where the genes
are linked in-frame (12). The resulting protein, named Quad 1, possesses four times the
mass of the native R67 DHFR monomer. Mutations were introduced using the PCR
based protocol outlined in the Quickchange kit from Stratagene. DNA sequencing was
performed by the University of TN sequencing facility to confirm all constructs.
Protein purification
E. coli STBLII cells (F -mcrA ∆(mcrB-hsdRMS-mrr) recA1 endA1 gyrA96 thi
supE44 relA1 λ -∆(lac-proAB); Gibco BRL) were used to maintain the tandem gene
arrays as well as express the monomeric R67 DHFR and mutants (17). Cells were grown
at 30°C with shaking for approximately 60 hours. The cells were lysed by sonication and
the crude protein extract was clarified with streptomycin sulfate and concentrated with
55% ammonium sulfate. The proteins were purified using the following chromatography
columns: G-75 Sephadex size exclusion column, DEAE Fractogel column, Biorad
HighQ column, and FPLC HighQ column (7,16). The purity of the proteins was
determined by SDS-PAGE.
Isothermal titration calorimetry
Binding affinities and the enthalpy associated with binding were monitored using
isothermal titration calorimetry (ITC) as previously described (1,4). Briefly,
measurements were carried out on a Microcal Omega Ultrasensitive Isothermal Titration
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Calorimeter equipped with a nanovoltmeter for improved sensitivity and connected to a
circulating water bath for temperature control. The data were automatically collected by
an IBM PC running DSCITC data acquisition software and were analyzed using Origin
version 2.9 software provided by the manufacturer. The design and operation of this
instrument have been described by Wiseman et al. (18). Samples typically consisted of
~90-100 µM protein in MTH buffer (50mM MES, 100mM Tris, 50mM acetic acid, and
10mM β-mercaptoethanol), pH 8. This buffer maintains constant ionic strength from pH
4.5 to 9.5 (19). Measurements were performed at 28oC. Ligand concentrations in the
syringe were typically 20 times the protein concentration. Addition of ligand to buffer
only was performed to allow baseline corrections. Data describing NADPH or DHF
binding were fit to an interacting sites model where the stoichiometry of ligand binding
was set equal to two. Data describing binding of NADP+ were fit to a single site model.
Ternary complex data were obtained by titrating DHF into a 1:1 mixture of R67
DHFR:NADP+ and were fit to a single site model.
Steady state kinetics
The kinetic behavior of each protein was monitored using a Perkin-Elmer λ3a
spectrophotometer controlled by an IBM PS2 (20). The data were collected using the
program UVSL3. Each experiment was conducted at 30°C in MTH buffer. Four to five
subsaturating concentrations of both DHF and NADPH were utilized to monitor activity.
To calculate kcat and Km values for those variants displaying no to minimal substrate or
cofactor inhibition, the data were fit globally to the nonlinear Michaelis-Menton equation
describing bisubstrate kinetics using SAS v8.2 (21; Smiley et al., manuscript in
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preparation). These values agree with the more traditional data analysis approach (22,
23) where primary linear 1/[substrate] vs 1/velocity plots are followed by secondary
plots, yielding kinetic parameters. To calculate kcat and Km values for those variants
displaying substantial substrate/cofactor inhibition, the data were fit globally using SAS
to a rate equation describing the R67 DHFR mechanism (4). The mechanism is shown in
Scheme I and the corresponding rate equation is:
kcat • [Etotal] • [DHF] • [NADPH]
v = -------------------------------------------------------------------------------{[DHF][NADPH] + Km (DHF) • [NADPH] + Km (DHF) • Kd1 (NADPH) +
Km (NADPH) • [DHF] + (Km (DHF) • [NADPH]2 / Kd2 (NADPH)) + (Km (NADPH) • [DHF]2/
Kd2 (DHF))}

(1)

where v is the velocity of the reaction; [Etotal], [DHF], [NADPH] are the concentrations of
enzyme, substrate and cofactor; and Kd1 and Kd2 are the first and second binding
constants for the specified ligands as measured by isothermal titration calorimetry (ITC).
In fitting these data sets, the Kd values obtained by isothermal titration calorimetry were
used as constraints. Since three Kd values are entered explicitly with bounds allowing
some minor variation, the fourth Kd is solved using a closed thermodynamic loop
relationship (Km (NADPH) = Kd1 (NADPH) • Km (DHF) / Kd1 (DHF)). To keep any variation from
funnelling to the fourth Kd, a ratio of Kd1 (NADPH) to Kd1 (DHF) was sometimes used as a
fixed parameter (again with bounds allowing some minor variation). In the fitting
process, the inputted Kd values and the Kd1 ratio were allowed to vary by 2-3 fold. If the
2-3 fold changes in Kd values gave better fits to the steady state kinetic data, then these
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Scheme 1. Binding scheme for R67 DHFR proposed from steady-state kinetics (16)
and isothermal titration calorimetry (4) studies.

46

Kd values were used to re-assess the ITC fits. All ITC refits remained within 90%
confidence intervals.
Protein and ligand concentrations were determined spectrophotometrically. For
all mutants, extinction coefficients were determined using the biuret assay (24). Ligand
concentrations were determined using the following extinction coefficients: 28,000
l/mol•cm at 282 nm for DHF (25) and 6230 l/mol•cm at 340 nm for NADPH (26). The
molar extinction coefficient used to assess DHFR reduction of DHF was 12,300 l mol1

cm-1 (27).

Results
Construction of an altered tandem array
Direct mutagenesis of the quadruplicated gene construct described in Bradrick et
al. (12) did not allow control of either the number of mutations or their placement since
each of the gene copies was identical. Therefore a different mutagenesis strategy was
devised. In this alternate approach, unique restriction sites were designed between the
gene copies by mutagenesis of the 5′ and 3′ ends of each of the single copy genes. This
process resulted in 4 different single R67 DHFR gene constructs. Introduction of an
asymmetric mutation into the desired gene copy was next performed and ligation of the
resulting constructs allowed reconstruction of the quadruplicated gene containing the
desired asymmetric mutation(s).
The tandem array containing the restriction sites but no asymmetric mutations is
named Quad 2. Figure 2 shows a Bcl1 site at the 5′ end of gene copy 1; an EcoRV site
separates gene copies 1 and 2; a KpnI site occurs between copies 2 and 3; an ApaI site
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Figure 2. Flowchart for construction of the quadruplicated R67 DHFR genes. The
complete R67 DHFR gene sequence is given in reference 16. Construction of the initial
quadruplicated gene, Quad 1, is described in reference 12. Each gene copy coding for a
78 amino acid monomer is denoted by a horizontal arrow. Partial DNA sequences with
engineered unique restriction sites (in bold) are shown below the line while the
corresponding amino acids are given above the line. For Quad 3, two additional
mutations were added; gene copy 1 contains a S59A mutation while gene copy 4
contains a H362L mutation (29).
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GENE COPY

GENE COPY

GENE COPY

GENE COPY

Quad 1
Start M1………..…. S59……….I77-N78-M101……. I177-N178-M201…. I277-N278-M301……H362…..N378 end
A
ATC-AAC-ATG…….CAC…AAC-TAA-TAGATG-ATC-AAG…TCT………TC-AAC-ATG………ATC-AAC-ATG…..
Bcl
EcoR

Quad 2
I77-N78D-M101I…I177R-N178Y-M201L….I277R-N278A-M301L…..H362……….N378 end
Start M1……………... S59…….
ATG-ATC-AAG…TCT……ATC-GAT-ATC…….AGG-TAC-CTC……….AGG-GCC-CTG……CAC..AAC-TAA-TAGBcl
EcoR
KpnI
ApaI
EcoR

Quad 3
Start M1………......S59A….....
I77-N78D-M101I....I177R-N178Y-M201L…. I277R-N278A-M3011L.. H362L……378
N
end
AAC-TAA-TAGATG-ATC-AAG….GCT....ATC-GAT-ATC……..AGG-TAC-CTC……… AGG-GCC-CTG….…..CTC….
Bcl
EcoR
KpnI
ApaI
EcoR
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divides genes copies 3 and 4; and an EcoR1 site is positioned at the 3′ end of gene copy
4. Introduction of the restriction sites in the gene creates several amino acid changes.
The C-terminal wt R67 DHFR sequence is Ile77-Asn78; for direct connection to the
second gene copy, the next residue would be Met101. However for the construct that
contains the EcoRV site, N78D+M101I mutations are present. For the construct that
introduces the KpnI site, I177R+N178Y+M201L mutations occur. Lastly, for the Apa I
restriction site, I277R+N278A+M301L mutations are introduced. While these changes
are not always conservative, a comparison of type II DHFR sequences indicates the Nterminal 26 residues and the C-terminal 2 residues are not well conserved (28). Further,
removal of the N-terminal 16 amino acids by chymotrypsin treatment does not affect
enzyme activity (16).
From an examination of the homotetramer structure, it appears feasible to form
either an ABCD or an ABDC topology or a mixture of the two species in the
quadruplicated gene product. This option arises as the N-terminal Pro19 residues from
the C and D monomers are equidistant (>45Å) from the C-terminal N78 residue in the B
monomer in the R67 DHFR crystal structure. These two symmetry related Pro19
residues are ~15 Å apart3. To constrain the various potential folding topologies to a single
ABCD domain arrangement, we introduced a S59A mutation in gene copy 1 and a
H362L mutation into gene copy 4.

Individually, the S59A and H62L mutations

destabilize the homotetramer, forming inactive dimers. However 1:1 mixtures restore
almost full activity, indicating they complement each other and form heterotetramers
The N-terminal 17-18 amino acids are disordered in the dimer structure (30) and when
16 N-terminal amino acids were cleaved off, the truncated protein crystallized as a
tetramer (3).
3
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(29). The quadruple variant containing these mutations is named Quad 3. All subsequent
mutants described below use this as a “parent”.
The final step in this process introduced Q67H mutations into Quad 3. A single
Q67H mutation was constructed in gene copy 1; single mutations in other gene copies
were not constructed as the 222 symmetry of R67 DHFR predicts they will be equivalent.
For double Q67H mutants, 3 non-equivalent constructs are possible. The first contains
mutations in gene copies 1&2 (=Q67H:1+2); the second contains Q67H mutations in
gene copies 1&3 (= Q67H:1+3); and the third contains Q67H mutations in gene copies
1&4 (=Q67H:1+4). In the 1+2 construct, Q67H lies next to a wt Q67 residue at the
“floor” as well as the “ceiling” of the pore and the mutations occur on the “left hand” side
of the pore. In the 1+3 construct, Q67H again lies next to a wt Q67 residue at the “floor”
of the pore, however the second Q67H mutation occurs “diagonally” across the pore on
the “ceiling.” In the Q67H:1+4 construct, a Q67H pair should form at the “floor” of the
active site pore while a wt Q67 pair should occur at the “ceiling”. From the symmetry,
the 1+2 construct should be equivalent to a 3+4 construct; the 1+3 and 2+4 constructs
should be equivalent as are the 1+4 and 2+3 constructs. Only one triple mutant,
Q67H:1+2+3, was constructed as was a single quadruple mutant, Q67H:1+2+3+4.
Figure 1 shows a cartoon of the mutant configurations.
Does the Quad 3 protein mimic WT R67 DHFR?
Prior to construction and evaluation of any asymmetric mutants, it was necessary
to assess the effect of the mutations that added the unique restriction sites between gene
copies, as well as the S59A and H362L mutations used to constrain possible folding
topologies to the quadruplicated gene product. To determine whether the Quad 3 protein
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mimics wt R67 DHFR, steady state kinetics and isothermal titration calorimetry were
utilized. Table 1 gives the kcat and Km values for wt R67 DHFR, the original Quad 1
protein (12) as well as the Quad 3 protein derived from this work. The kcat and Km values
for Quad 3 are similar to those of Quad 1 and are within a factor of 2 of wt R67 DHFR,
indicating the effects of the mutations are minor.
A comparison of ITC binding data for NADPH, DHF and NADP+ is given in
Table 2. Again, the Quad 3 protein mimics wt R67 DHFR reasonably well. The largest
difference is an approximately 5 fold weaker binding of the first DHF molecule.
However the previously reported Kd values for DHF binding to wt DH→sFR were fit
including the first data point (4). In contrast, the values reported in this study do not use
the first data point due to its variability associated with the first mixing event in the
calorimeter. This difference in fitting explains an approximately 2 fold change in Kd.
Any additional variance arises from differences between the Quad 3 and wild type
proteins.
What are the effects of the asymmetric Q67H mutations?
To assess the effects of the Q67H mutations on ligand binding, ITC was used to
monitor binding to DHF, NADPH, and NADP+ in various combinations. A
representative titration is given in Figure 3. Data for all mutants were obtained except for
the Q67H:1+2+3+4 variant. We find the data for this species are not readily
reproducible as the protein solution often is turbid after the titration, indicating
aggregation at high protein concentrations.
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Table 1. A comparison of steady state kinetic values at pH 7.0 for numerous R67
DHFR constructs.
Enzyme Variant

kcat (sec-1)

Km (NADPH) (µM)

Km (DHF)

R2
(SAS)

(µM)
WT R67 DHFRa

1.3

3.0

5.8

-

Quad 1b

0.75

4.5

8.0

-

Quad 3c

0.81 ± 0.02

4.4 ± 0.4

6.7 ± 0.4

90%

Q67H:1c

0.23 ± 0.01

1.3 ± 0.1

3.6 ± 0.2

90%

Q67H:1+2d

0.21 ± 0.01

0.28 ± 0.02

3.6 ± 0.3

89%

Q67H:1+3 d

0.23 ± 0.01

1.8 ± 0.1

11 ± 0.6

97%

Q67H:1+4 d

0.15 ± 0.01

0.95 ± 0.14

2.6 ± 0.5

84%

Q67H:1+2+3d

0.090 ± 0.01

0.45 ± 0.06

7.5 ± 2.3

85%

Q67H:1+2+3+4d

0.10 ± 0.01

0.026 ± 0.004

0.13 ± 0.02

86%

Q67H R67 DHFR
0.022 ± 0.001 0.03 (calculated) 0.16 ± 0.005
e
(pH 8)
Q67H R67 DHFR
0.025 ± 0.001
0.014 ± 0.002
0.14 ± 0.01
91%
f
(pH 8)
a
Values from reference 16.
b
Values from reference 12.
c
Global non-linear fit to the Michaelis-Menton equation describing bisubstrate kinetics
using SAS.
d
Global non-linear fit (SAS) to a rate equation describing the R67 DHFR mechanism
(eq 1) using ITC values as constraints.
e
Fit values from reference 1 using FITSIM.
f
Global non-linear fit (SAS) to a rate equation describing the R67 DHFR mechanism
(eq 1) using ITC values as constraints.
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Table 2. A comparison of wt R67 DHFR with Quad 3 using isothermal titration
calorimetry to monitor ligand binding.

a

b

Complex

Kd (µM)

∆H (cal/mol)

Stoichiometry

Wt R67 DHFR with
NADPHa

5.0 ± 0.3
48 ± 2

-8600 ± 200
-5800 ± 2500

1.56 ± 0.14

Quad 3 with NADPH

4.0 ± 0.3
37.1 ± 3.0

-3000 ± 26
-9400 ± 83

2b

Wt R67 DHFR with
DHFa

250 ± 50
4.4 ± 0.7

-7900 ± 900
-1400 ± 60

1.88 ± 0.1

Quad 3 with DHF

46 ± 0.7
2.0 ± 0.02

-8420 ± 110
-3750 ± 39

2b

Wt R67 DHFR with
NADP+a

99 ± 3

-7700 ± 500

0.99 ± 0.03

Quad 3 with NADP+

31.3 ± 1.3

-7000 ± 450

0.95 ± 0.02

Wt R67 DHFR • NADP+
with DHFa

4.8 ± 1.0

-11700 ± 300

1.22 ± 0.01

Quad 3 • NADP+ with
DHF

4.9 ± 0.1

-11500 ± 800

0.99 ± 0.01

Results from reference 12. Microscopic values (kd1, kd2) are reported. The
statistical relationship between microscopic and macroscopic constants is Kd1 = ½
kd1 and Kd2 = 2 kd2 (52).
The stoichiometry is set at 2 by choosing the two interacting sites model in Origin,
the software used by the ITC for fitting the data. Since the value is set, it is
presented with no error.
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Figure 3. Isothermal titration calorimetry analysis of DHF binding to Q67H:1+4
DHFR. The protein concentration was 100 µM and the data were fit using the 2
interacting sites model (dotted line). Best fit values are given in Table 4. To fit
the steady state kinetic data (table 1), the ITC values were allowed to vary up to 3
fold from the best fit values. In fitting of the kinetic data, the (microscopic) Kd
values for DHF binding to Q67H:1+4 shifted to Kd1 = 2.12 and Kd2 =106 µM.
These involve a 2.3 fold increase and a 3 fold decrease from the Kd values given in
Table 4. The refit is shown by the solid line.
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Table 3 gives the Kd and ∆H values associated with binding of NADP+. Only one
NADP+ binds per R67 DHFR as compared to 2 NADPH molecules. This different
stoichiometry is likely due to charge-charge repulsion between the positively charged
nicotinamide rings in NADP+. A trend noted is introduction of each successive Q67H
mutation results in tighter binding of NADP+ over a 7-fold range (with some variability
for the different topologies of the double mutants). A generally linear relationship
between the number of mutations and the Kd is consistent with no conformational
changes upon binding and additive (independent) interactions between the Q67H residues
(30). While a model does not exist for bound NADP+, a model for bound, reduced NMN
has recently been generated by docking NMNH into R67 DHFR•FolI, where Fol1 is the
productively bound pteridine ring in the crystal structure (6). In this model, the reduced
nicotinamide moiety of NMN interacts with one pair of symmetry related Q67 residues,
while the pteridine ring of FolI interacts with the other pair of Q67 residues. One
interpretation of the above ITC results suggests that bound NADP+ interacts with at least
three of the Q67 residues since successive addition of up to 3 mutations continues to
tighten binding. This scenario would require NADP+ to bridge between both pairs of
Q67 residues, a distance of ~11A (between carboxamide atoms). This interpretation
suggests some alteration of the binding mode for NADP+ with respect to that proposed
for reduced NMN in a ternary complex. An alternate hypothesis is that when NADP+
binds to either wt or Q67H R67 DHFRs, the binding constant reflects the statistical
average of binding at each symmetry related site. Since the sites are equivalent in the
homotetramer, statistical averaging has no effect. However when NADP+ binds to an
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Table 3. Binding of NADP+ to the various DHFR species as monitored by ITC at pH
8.0.

a

Complex

Kd (µM)

∆H (cal/mol)

stoichiometry

Quad 3 titrated with
NADP+

31.3 ± 1.3

-7000 ± 450

0.95 ± 0.02

Q67H:1 with NADP+

19.3 ± 1.9

-6500 ± 250

1.1 ± 0.03

Q67H:1+2 with NADP+

13.1 ± 1.0

-7600 ± 240

1.1 ± 0.02

Q67H:1+3 with NADP+

15.3 ± 1.4

-6300 ± 340

1.1 ± 0.01

Q67H:1+4 with NADP+

11.2 ± 1.0

-13,900 ± 520

1.0 ± 0.04

Q67H:1+2+3 with
NADP+

4.23 ± 0.3

-12,200 ± 220

1.1 ± 0.05

Q67H R67 DHFR with
NADP+a

3.4 ± 0.9

-9900 ± 500

0.70 ± 0.05

Results from reference 1.
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asymmetric mutant, for example Q67H:1, there are several possible binding orientations,
i.e. one symmetry pair of orientations would place the nicotinamide ring near a wt Q167Q267 homo-pair while a second pair of orientations would juxtapose the nicotinamide
ring near the Q67H-Q367 hetero-pair. If the contribution of the Q67H residue to the
overall binding constant is minor, the observed Kd may be an average value reflecting the
contributions associated with binding at non-equivalent sites. As the number of Q67H
mutations increases, this would lead to an overall decrease in the apparent Kd. This
explanation seems more likely than the model where NADP+ interacts with ≥ 3 Q67H
residues, although that cannot be ruled out.
A more complex relationship arises when the effects of the Q67H mutations on
binding NADPH or DHF (binary conditions) are assessed. Table 4 gives the Kd and ∆H
values observed. Several observations are apparent. First, for DHF binding, the addition
of 1 Q67H mutation has a large, immediate effect on the first Kd value, while for NADPH
binding, it takes 3 mutations to show any advance towards the tighter binding previously
observed in the Q67H homotetramer (1). Second, the various double mutants show
different binding patterns, particularly for DHF, indicating they present different
arrangements of the Q67H mutations. This implies that the Quad 3 parent protein has
been locked into a single topology (ABCD) and that the effect of two Q67H mutations is
a function of how they are arranged with respect to each other. Third, the cooperativity
between ligands (monitored by Kd2 / Kd1) shows large variations, particularly for binding
of DHF. These issues are discussed more fully below.
Since NADP+ binding gets progressively tighter with the successive addition of
Q67H mutations, a straightforward result for binding of NADPH would have been a
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Table 4. Results of binding studies at pH 8.0 using isothermal titration calorimetry.

a

Complex

Kd (µM)

∆H (cal/mol)

Kd2 / Kd1

Quad 3 with NADPH

4.0 ± 0.3
37.1 ± 3.0

-3000 ± 26
-9400 ± 83

9.3

Q67H:1 with NADPH

3.6 ± 0.8
53.5 ± 6.5

-5800 ± 95
-9830 ± 160

15

Q67H:1+2 with NADPH

2.7 ± 0.1
15.0 ± 0.4

-5030 ± 28
-3530 ± 32

5.6

Q67H:1+3 with NADPH

8.7 ± 0.5
51.1 ± 3.2

-8650 ± 59
-5030 ± 91

5.9

Q67H:1+4 with NADPH

17.7 ± 0.8
16.1 ± 0.5

-8540 ± 100
-14,000 ± 165

0.91

Q67H:1+2+3 with
NADPH

0.21 ± 0.01
3.5 ± 0.07

-3740 ± 20
-2900 ± 75

17

Q67H R67 DHFR with
NADPHa

0.054 ± 0.016
0.31 ± 0.06

-4800 ± 100
-2500 ± 400

5.7

Quad 3 with DHF

46 ± 0.7
2.0 ± 0.02

-8420 ± 110
-3750 ± 39

0.043

Q67H:1 with DHF

0.88 ± 0.06
2.0 ± 0.05

-6340 ± 46
-5770 ± 74

2.3

Q67H:1+2 with DHF

0.97 ± 0.04
1.1 ± 0.02

-6250 ± 44
-5740 ± 45

1.1

Q67H:1+3 with DHF

1.5 ± 0.05
20 ± 0.6

-8500 ± 260
-1100 ± 33

13

Q67H:1+4 with DHF

0.93 ± 0.03
320 ± 16

-7340 ± 31
-3360 ± 23

340

Q67H:1+2+3 with DHF

0.21 ± 0.1
0.64 ± 0.1

-7350 ± 76
-7270 ± 82

3.0

Q67H R67 DHFR with
DHFa

0.040 ± 0.008

-8000 ± 100

identical
sites

Results from reference 1.
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similar trend. Instead, addition of 1 Q67H mutation has a minimal effect on NADPH
binding. Addition of two mutations has observable effects on binding, particularly for
the Q67H:1+4 configuration, but tight binding is not observed. Only when three Q67H
mutations are introduced does tighter binding begin to appear. While we would expect
the Q67H:1+2+3+4 mutant to mimic the Q67H homotetramer and display 100 fold lower
Kd values, we are unable to confirm this prediction due to protein aggregation.
The non-linearity between the number of Q67H mutations and the corresponding
NADPH Kd values suggests conformational changes may occur. These changes could
describe altered interactions between either the wild type Q67 and mutant Q67H residues
and/or between the 2 ligands. The first alternative appears feasible as the Q67 residues
occur very near the 222 symmetry operator and each Q67 residue interacts with its
symmetry related partner. Therefore it would not be surprising if introduction of a Q67H
mutation alters the position of the other member of the pair. Another possibility to
explain the binding data is that the cooperativity between the 2 NADPH molecules is
altered. One measure of the interligand cooperativity is given by the ratio of Kd2/Kd1. As
seen in Table 4, this ratio varies from a low of 0.91 to a high of 17 depending on the
number of mutations introduced as well as the positioning of the double mutants. We
previously observed that this ratio varies less than 2 fold when studying NADPH binding
to various homotetrameric R67 DHFR mutants (Q67H, I68L, Y69F; refs 1,7). This
minimal variance of the Kd2 to Kd1 ratio was striking as the Kd values themselves varied
over 3 orders of magnitude! From those studies, we concluded that interligand
cooperativity is important in binding and catalysis in R67 DHFR and must be linked to
the symmetry of the active site pore. Therefore the data given in Table 4 are the first
60

examples of varying levels of cooperativity associated with NADPH binding to R67
DHFR. We also find support for interligand cooperativity modulating the nonlinear
effects of the asymmetric Q67H mutations on NADPH binding as the transition from a
relatively linear relationship between the number of mutations and log Kd to a clearly
non-linear relationship occurs as the binding stoichiometry goes from one (NADP+) to
two (NADPH). This difference suggests the conformational changes could also arise
from ligand-ligand interactions. The main differences between NADP+ and NADPH are
the positive charge and aromaticity of the nicotinamide ring in NADP+.
In contrast to the above results with NADPH, binding of DHF shows a clear
effect upon addition of one Q67H mutation. Binding is tightened to the first DHF
molecule by a factor of 52, suggesting a direct interaction between the Q67H mutation
and DHF. The second Kd is also tight. Since the remaining residues are wt, this result
suggests positive cooperativity remains between the two DHF molecules. Addition of 2
mutations shows varying results, depending on the configuration of the Q67H residues.
For the Q67H:1+2 double mutant, both Kd values are relatively tight, suggesting either
that each DHF is responding to the presence of the Q67H and Q167H mutations at the
“floor and ceiling” of the pore, or that positive cooperativity remains between the two
DHF molecules. For the Q67H:1+3 and Q67H:1+4 double mutants, positive
cooperativity between the DHF molecules clearly does not occur and 2 possibilities can
be envisioned to explain the binding pattern. Either the two DHF molecules now bind
differently enough so that negative cooperativity occurs between them or binding of the
first DHF molecule is tight due to the presence of the Q67H mutations while binding of
the second DHF molecule remains weak due to the interactions with the wt Q67 residues.
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For the latter, minimal to no DHF-DHF interactions would be expected. Alternatively,
conformational changes associated with the mutations may be occurring as the Kds for
the Q67H:1 mutant are different from the Q67H:1+4 mutant. In these mutants, either 1
or 2 mutations occur at one interface while the other interface possesses only wt residues.
If the second DHF binding event was responding only to the wt Q167-Q267 residues,
then similar values would be expected for these Kds. This is not observed. Finally, the
introduction of 3 Q67H mutations also tightens binding to both DHF sites, although the
effect is not as dramatic as for NADPH binding. That 3 mutations can continue to affect
the first Kd also supports a model where conformational changes are occurring, either via
altered interactions between the wild type Q67 and mutant Q67H residues and/or between
the 2 ligands. The latter model where ligand-ligand interactions influence the binding
behavior remains feasible, as positive cooperativity between DHF molecules is observed
in Quad 3 while no to negative cooperativity patterns are detected for the various Q67H
asymmetric mutants.
Addition of DHF to R67 DHFR•NADP+ to form a ternary complex was
additionally monitored by ITC methods. The Kd values are given in Table 5. Only minor
variations are observed, indicating the affinity of DHF for R67 DHFR•NADP+ remains
fairly constant throughout this series. To monitor interligand cooperativity between DHF
and NADP+, we have continued to use a ratio of the Kd for the second binding event
divided by the Kd for the first binding event. In this case, the ratio is the Kd of DHF
binding to R67 DHFR•NADP+ divided by the Kd for NADP+ binding to R67 DHFR. The
cooperativity values remain mostly constant and indicate positive cooperativity between

62

Table 5. Ternary complex formation monitored by ITC.
Complex

a

Kd (µM)

∆H (cal/mol)

stoichiometry

Kd (DHF ternary)/
Kd (NADP+ binary)

Quad 3 • NADP+
with DHF

4.9 ± 0.1

-11500 ± 800

0.99 ± 0.01

0.16

Q67H:1 • NADP+
with DHF

2.2 ± 0.05

-11400 ± 940

1.0 ± 0.01

0.11

Q67H:1+2 • NADP+
with DHF

4.5 ± 0.1

-9400 ± 400

0.94 ± 0.01

0.34

Q67H:1+3 • NADP+
with DHF

4.8 ± 0.1

-9400 ± 600

1.07 ± 0.01

0.31

Q67H:1+4 • NADP+
with DHF

2.0 ± 0.05

-10000 ± 370

1.03 ± 0.01

0.18

Q67H:1+2+3 •
NADP+ with DHF

6.6 ± 0.2

-8500 ± 590

1.01 ± 0.03

1.6

Q67H R67 DHFR •
NADP+ with DHFa

6.7 ± 0.3

-9000 ± 450

0.82 ± 0.04

2.0

Results from reference 1.
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the ligands, except for the Q67H:1+2+3 mutant, which indicates negligible or a slight
negative cooperativity.
Steady state kinetics of asymmetric mutants
The asymmetric mutants were additionally evaluated by steady state kinetic analysis.
The values were readily determined for Q67H:1 using SAS to globally fit all the data to
the Michaelis Menton equation describing bisubstrate kinetics. The data and a 3D
representation of the fit are shown in Figure 4a; best fit values are given in Table 1. Each
grid line on the 3D plot corresponds to a constant first ligand concentration with varying
second ligand concentrations (and vice versa). The Km values both decrease ~1.5 fold
and kcat decreases 3 fold. These values agree with those determined by data linearization,
followed by secondary replots (22, 23).
Analysis of the kinetic data for the other mutants is less straightforward as they
display various levels of substrate and cofactor inhibition. Therefore a rate equation (eq
1) was derived for the mechanism describing inhibition associated with formation of the
2 non-productive complexes, NADPH•NADPH or DHF•DHF (4). The steady state
kinetic data were then fit globally using SAS; the Kd values obtained by ITC were
entered as constraints. Since the mechanism predicts formation of the NADPH•NADPH
or DHF•DHF complexes as well as the productive NADPH•DHF complex, this fitting
method requires data to cover a wide range of substrate/cofactor “space” describing
catalysis as well as inhibition. Therefore >130 but <370 data points were used in these
fits.
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Figure 4. Steady state kinetic data for various R67 DHFRs. Panel A describes the
Q67H:1 R67 DHFR, which was fit to the Michaelis-Menton equation describing
bisubstrate kinetics using SAS. Data points above and below the calculated 3D plot
are filled and hollow stars respectively. Panel B describes the Q67H homotetramer
data (Park et al., 1997a). This representation reverses the axes for [DHF] and
[NADPH] to accentuate a “ridgeline” of maximal activity. Nonlinear fitting was
performed by SAS to equation 1 and Table 1 gives the best fit values. Kd values
derived from ITC data were used as constraints in fitting with 2-3 fold variations
accepted if the ITC data could be reasonably refit with these values. Panel C
describes the Q67H:1+2 data as well as its accompanying 3D fit. The plots for the
Q67H:1+3 and Q67H:1+4 double mutants are given as supplementary information in
the appendix.
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Since global nonlinear SAS analysis of steady state kinetic data to a complicated
rate equation is a new approach, we first confirmed its ability to fit the Q67H
homotetramer data that had previously been analyzed with the computer program,
FITSIM (1,31). Our FITSIM analysis at that time indicated the Q67H homotetramer data
could not be fit well without varying the ITC Kd values 2-3 fold. These alterations arose
as NADPH was observed to be more inhibitory than DHF, even though the Kd values
were similar. To fit the kinetic data, both NADPH Kd values were decreased 3 fold and
both DHF Kd values were increased 2 fold. In this scenario, NADPH binds more tightly
than DHF, providing more inhibition. SAS was able to identify this solution. In
addition, SAS identified a second possibility where the cooperativity patterns were
altered. In this solution, neither Kd1 for NADPH or DHF were altered, but reduced
negative cooperativity was proposed between the two NADPH molecules as well as the
introduction of negative cooperativity between the two DHF molecules. In this second
model, the NADPH•NADPH complex forms more easily than expected as its Kd values
are closer, while it is harder to form the DHF•DHF complex as its Kd values are farther
apart. A comparison of the correlation coefficient (R2) for these 2 different fits supports
the first SAS solution. Figure 4b shows the data overlaid on a 3D representation of the fit
for the Q67H homotetramer. A good fit is observed with a R2 value of 91%; best fit
values are given in Table 1. This analysis clearly validates the SAS global fitting
approach.
Analysis of the steady state kinetic data for the other asymmetric mutants was
therefore performed using SAS. The data set for the Q67H:1+2 mutant as well as a 3D
representation of the fit are given in Figure 4c. The data and 3D plots show
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substrate/cofactor inhibition at low second ligand concentrations. The fit values for this
asymmetric mutant as well as the others are given in Table 1.
Each double mutant displays different kinetic behavior, indicating the various
topologies generate different responses. The Q67H:1+2 double mutant displays obvious
cofactor inhibition, its kcat value decreases ~3 fold and Km values decrease ~16 and 2 fold
for NADPH and DHF respectively, leading to a 4 fold increase in kcat/Km (NADPH). The
next double mutant, Q67H:1+3, exhibits cofactor and substrate inhibition (particularly at
low second ligand concentration) as well as a ~4 fold decrease in kcat, a 2.5 fold decrease
in Km (NADPH) and a slight (1.6 fold) increase in Km (DHF). The Q67H:1+4 double mutant
displays no obvious substrate or cofactor inhibition and is readily saturated. While kcat
decreases ~6 fold, Km (NADPH) decreases 5 fold, yielding an approximately equal kcat/Km
(NADPH)

value to that of Quad 3. Km (DHF) decreases approximately 3 fold. The Q67H:1+2

double mutant is the most functional with respect to kcat/Km (NADPH) values while the
Q67H:1+4 double mutant maintains its catalytic efficiency with no obvious
substrate/cofactor inhibition. In fact, a fit of the Q67H:1+4 data to the bisubstrate
kinetics equation provides very similar fit values.
The triple mutant shows more obvious NADPH and DHF inhibition, and the
corresponding fit indicates a further decrease in kcat, and Km values that remain within the
range of the double mutants. The quadruple mutant displays increasing levels of NADPH
and DHF inhibition, similar to that of the Q67H homotetramer (1). The data set for the
Q67H:1+2+3+4 mutant was fit using the ITC Kd values measured for the Q67H
homotetramer as constraints; the values were allowed to deviate up to 4 fold (within
range of the Q67H:1+2+3 mutant). For the quadruple mutant, kcat decreases 8 fold with
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respect to Quad 3, while Km (NADPH) decreases 170 fold and Km (DHF) decreases 48 fold.
This leads to a 21 fold increase in kcat / Km (NADPH) which is accompanied by tighter
binding of NADPH and DHF at symmetry related sites, resulting in severe
cofactor/substrate inhibition. The similarity between kinetic values suggests the
Q67H:1+2+3+4 quadruple mutant mimics the Q67H homotetramer reasonably well.
To deal with fitting the kinetic data, SAS varied the Kd constraints by various
combinations of 2 approaches: by either maintaining the cooperativity but changing the
overall Kd values 2-3 fold (the Q67H:1+2+3, Q67H:1+2+3+4 and Q67H homotetramer
data sets) and/or by altering the cooperativity between ligands. For example, in the
Q67H:1+2 data set, negative cooperativity between NADPH molecules was weakened (8
fold) while negative cooperativity between the two DHF molecules was enhanced (2
fold). For the Q67H:1+3 data set, cooperativity between NADPH molecules was
maintained while binding was strengthened (3 fold), but the negative cooperativity
between DHF molecules was enhanced (6 fold). For the Q67H:1+4 data set, negative
cooperativity was enhanced between NADPH molecules (9 fold, ie a 3 fold tighter
binding of the first NADPH and a 3 fold weaker binding of the second NADPH), while
negative cooperativity was weakened between DHF molecules (7 fold). To fit the kinetic
data with reasonable R2 values required changes in the ITC constraints. Two to three fold
changes in Kd values were tolerated by the ITC refits reasonably well.
Effects of the mutations on protein structure
To confirm that all the Quad 3 protein variants are monomeric, gel filtration
studies were performed to assess how the oligomeric state varies as a function of pH. All
measurements confirm the protein is a monomer at both pHs 5 and 8 (data not shown).
69

We further assessed the level of structural change by monitoring the equilibrium between
“closed” and “open” forms of the quadruplicated gene product (which correspond to the
tetrameric and dimeric forms in wt R67 DHFR) using protein fluorescence. This titration
monitors the pKa of the symmetry related H62 residues (of which 3 remain in Quad 3 as
it contains a complementing S59A and H362L pair) by the fluorescence of nearby W38
residues (11,12). The behavior of Quad 3 continues to mimic that of Quad 1 while the
Q67H mutations slightly destabilize the “closed” structure (see Figure 8 and Table 6 in
the appendix). All proteins are in the active (“closed”) form for activity measurements at
pH 7 and ITC measurements at pH 8.
Since the non-additive nature of the kinetic and binding data suggest either a
conformational change in the protein or alterations in the ligand-ligand interactions, we
assessed the effect of the mutations on protein structure by CD measurements. There is
some variation in the CD signal (not shown). The largest change is observed in the
Q67H:1+2+3+4 mutant, however this signal change correlates with that previously seen
for the Q67H homotetramer (1). While these spectral changes may reflect some degree
of conformational change, they also could arise from the proximity of the Q67H mutation
to W38 (~3.7-4A), as Woody (32) indicates aromatic side changes can make detectable
contributions to the far-UV CD signal.
Discussion
The Q67H homotetramer has been observed to bind both NADPH and DHF more
tightly (>100 fold) than wild type R67 DHFR (1). Linked to this behavior was a 6.8 fold
decrease in kcat, resulting in a 3.6 fold enhancement in kcat/Km (NADPH). However the
ability of the Q67H mutant to reach its transition state was compromised by tighter
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binding of a second identical ligand at a symmetry related site, leading to substantial
cofactor and substrate inhibition. Therefore the symmetry in the active site pore imposes
a balance between catalysis and inhibition. Introduction of asymmetric mutations was
pursued to determine if tight binding of the transition state could be uncoupled from
inhibition. We reasoned if addition of 1-2 mutations was sufficient to tighten binding at
one binding surface, the remaining wildtype residues at the other binding surface might
not invoke tight binding and inhibition could be blocked. We address these linked issues
by discussing the interligand cooperativities as measured by ITC, followed by steady
state kinetic analysis.
What is the role of interligand cooperativity in R67 DHFR?
Our previous mutations at Q67, I68 and Y69 in the context of the homotetramer
(i.e. 4 mutations per active site pore) show minimal to no changes in NADPH
cooperativity over a 1000 fold change in binding affinity (1,7). We previously
interpreted this result as indicating either changes in affinity occur at all symmetry related
sites leading to similar effects and/or that interligand cooperativity is quite important in
ligand binding/catalysis. This is the first case where significant changes in NADPH
cooperativities have been observed in R67 DHFR. Essentially no cooperativity between
2 NADPH molecules is observed for the Q67H:1+4 double mutant while a 17 fold
difference exists between the Kd values for the Q67H:1+2+3 mutant. Further the
DHF•DHF interaction varies dramatically with Quad 3 displaying positive cooperativity
and the Q67H:1+4 mutant possessing either independent sites or negative cooperativity.
The range of Kd2/Kd1 for DHF binding varies from 0.043 to 340, a 7,900 fold effect.
Formation of the NADP+•DHF ternary complex also shows effects over a 10 fold range.
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That the cooperativity between NADP+ and DHF is least affected suggests a preference
for the hetero-ligand complex, a catalytic advantage that R67 DHFR utilizes.
Figure 5 compares the cooperativities between the various 2 ligand complexes, where
cooperativity measures the Kd for binding of the second ligand divided by the Kd for
binding the first ligand. Quad 3 shows negative cooperativity between the 2 NADPH
molecules, positive cooperativity between the two DHF molecules and positive
cooperativity between NADP+ and DHF, i.e. ternary complex formation. To increase
catalytic efficiency, these traits should either be enhanced or alternately, the strong
positive cooperativity between the two DHF molecules could theoretically be replaced by
a strong negative cooperativity. Negative cooperativity patterns are observed for the
Q67H:1+3 and Q67H:1+4 double mutants. How does this translate into steady state
kinetic behavior? Also the cooperativity ratios for the triple mutant show the most
convergence. Does this correlate with an inability to discriminate between the various
complexes?
Patterns of steady state kinetic behavior
As discussed above, 2 issues arise in R67 DHFR catalysis. The first is
stabilization of the productive ternary complex leading to the transition state. The second
issue arising from the 222 symmetry of the active site pore is competing formation of
inhibitory complexes. To express this in an energy landscape perspective, R67 DHFR
binds 3 complexes, DHF•DHF, NADPH•NADPH or NADPH•DHF. To enhance
catalysis, R67 DHFR can either stabilize the NADPH•DHF complex and/or destabilize
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Figure 5. A bar graph comparing cooperativity ratios for the various protein
constructs. The cooperativity between the first and second bound NADPH molecules
(hatched bar) is described by Kd2 / Kd1 (see Table 4). The cooperativity between the
DHF molecules (light gray bar) is given by Kd2 / Kd1 (see Table 4). The cooperativity
between NADP+ and DHF (dark gray bar) is given by Kd DHF ternary / Kd NADP+ binary (see
Table 5). Data for the Q67H homotetramer were from reference 1.
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the NADPH•NADPH and DHF•DHF complexes. The latter approach is termed negative
design (33-35).
This second issue arises when considering the steady state kinetic behavior of the
Q67H mutation series. Increasing levels of substrate/cofactor inhibition are noted as the
number of mutations increases, with Quad 3 showing no evidence of inhibition in the
assay concentrations used (6-121µM NADPH, 4-112 µM DHF), the double mutants
exhibiting zero to moderate levels of inhibition and the triple and quadruple mutants
displaying severe inhibition. Quad 3 appears to have evolved a reasonable binding
surface that achieves a low free energy state for the NADPH•DHF complex coupled with
a large free energy difference between productive and non-productive complexes. While
addition of Q67H mutations slightly alters binding to the NADPH•DHF complex, a large
energy difference between the NADPH•DHF complex and the NADPH•NADPH and
DHF•DHF states is no longer maintained, resulting in increasing levels of inhibition.
The competition between the three ligation states can clearly be seen in the 3D
plots describing bisubstrate kinetics. We begin this discussion considering the simple 3D
plot for Q67H:1 which shows no inhibition at the concentrations shown (figure 4a).
Hyperbolic (2D) plots can be seen on all 4 vertical edges of the cube and a plateau can be
seen at the upper back corner of the cube as Q67H:1 approaches its kcat value (0.23 sec-1)
at a 1:1 ratio of DHF to NADPH. In contrast, the Q67H homotetramer (Figure 4b) shows
that at low levels of DHF, addition of NADPH is inhibitory due to formation of the
NADPH•NADPH complex (2D plot on right face of cube). At high concentrations of
NADPH, addition of DHF displays hyperbolic kinetics (back face of cube), but since the
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enzyme is strongly inhibited due to formation of the NADPH•NADPH complex, the only
possibility is for the activity to rise. This curve does not reach kcat (0.025 sec-1) as there is
always some level of inhibition present. At low levels of NADPH, addition of DHF is
inhibitory due to formation of the DHF•DHF complex (front face of cube). At high
concentrations of DHF, addition of NADPH shows initial hyperbolic kinetics followed by
inhibition (left face of cube). Again since the enzyme is strongly inhibited under these
high DHF conditions, the activity can only increase. The rate increases until the NADPH
concentration becomes high enough to be inhibitory and the NADPH•NADPH complex
forms (back corner of cube). The kcat is never reached anywhere on the surface of this 3D
plot. A “ridgeline” that describes maximal activity can be clearly seen. The “ridgeline”
appears to correspond to a 1:1 ratio of DHF to NADPH, modified by the relative
inhibitory capacities of the DHF•DHF to the NADPH•NADPH complexes.
Another way to consider the kinetic results is that the cooperativity patterns for
the various double mutants vary substantially, yet kcat is barely affected. This behavior
indicates the cooperativity associated with reaching the productive ternary complex state
has not changed dramatically (see Table 5). What has changed is the ability of the
NADPH•NADPH and/or DHF•DHF complexes to compete favorably for formation.
When these dead-end complexes readily form, the ability of the mutant enzyme to reach
kcat decreases. This is clearly shown in Figure 4b for the Q67H homotetramer.
Role of Q67H in interligand interactions?
Gene duplication followed by divergence is commonly proposed as a mechanism
of enzyme evolution. In this study, we quadruplicated the gene for R67 DHFR and
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introduced various combinations of Q67H mutations. While addition of the Q67H
mutation in the homotetramer tightens binding to both ligands by a factor of 100, this
effect does not appear in an additive fashion as increasing numbers of Q67H mutations
are added asymmetrically to the quadruplicated gene product. This study of gradually
breaking the symmetry of the binding surface suggests one consequence of the symmetry
is overdetermination of the binding interactions, particularly for the heteroligand
complex. While addition of a single Q67H mutation might be expected to provide one
mutation has minimal effects on catalysis. For example while similar Kd values for tight
binding interaction that would enhance binding, we find introduction of a single binding
two DHF molecules leads to the prediction of DHF inhibition in the Q67H:1 variant,
none is observed. This suggests the remaining wt sites maintain their function and are
strongly preferred during catalysis. If a pair of Q67 residues need to interact to provide
one tight binding surface, then the Q67H:1+4 double mutant would be expected to
enhance binding as these mutations form a pairwise interaction. This double mutant
shows larger effects on ligand binding, but minimal effects on kcat, again suggesting an
overdetermination of the binding sites with a preference for wt sites. As 3-4 mutations
are added, increasing effects on catalysis are noted, with the ability of the enzyme to
discriminate between the productive ternary complex and nonproductive homoligand
complexes becoming compromised. While the 222 symmetry in R67 DHFR imposes
numerous deleterious effects on binding and catalysis, overdetermination of the binding
site suggests an evolutionary advantage for symmetry as asymmetric mutations are
introduced.
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An alternate, but linked, point of view suggests that while protein interactions are
important, the symmetry in R67 DHFR has selected for a strong influence arising from
hetero-ligand interactions. While the NADP+•DHF complex is not the catalytic species, it
provides a reasonable mimic. The ternary complex Kd values (Table 5) as well as the kcat
values (Table 1) suggest that the hetero-ligand interactions are maintained (for the most
part) in all the asymmetric mutants and perhaps drive binding. Additional support for
this point of view comes from an ab initio quantum mechanical calculation that predicts
the endo transition state (where the nicotinamide ring overlaps the more bulky side of the
pteridine ring) is 2-8 kcal/mol more stable than the exo transition state (with minimal
overlap of the pteridine and nicotinamide rings; 36,37). Interligand NOE NMR data also
favor R67 DHFR using an endo transition state (5) as do our docking studies focused on
generating a ternary complex model (6). Some degree of ring stacking may allow R67
DHFR to partition binding towards the ternary complex.
While Q67 appears to play a minimal role in formation of the NADPH•DHF
complex, it appears more active in discriminating against formation of the
NADPH•NADPH and DHF•DHF complexes. To describe how the Q67H mutations
affect the 2DHF and 2NADPH complexes will require better models of these complexes.
From the crystal structure of R67 DHFR•folate•folate, the N1 and N3 containing rings of
the pteridine moieties overlap (3). More recent studies monitoring interligand NOEs
(ILOEs) in R67 DHFR (5) describe a folate•2-deamino-2-methyl-5,8-dideazafolate
complex with a similar overlap of the N1, N3 containing rings of the pteridines. In
contrast, no structural information is available about the NADPH•NADPH complex.
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How does R67 DHFR differentiate between these various complexes? Perhaps a clue
comes from our ITC studies that measure the enthalpies associated with ligand binding.
Figure 6 shows a plot of ∆H vs. T∆S for the various complexes. Binding can be
altered in mutant enzymes by different degrees of hydrogen bonding and van der Waals
contacts which in turn can alter the degrees of freedom of the ligand and amino acid side
chain (38,39). The former would affect ∆H, the latter, T∆S. Solvent re-organization may
be involved in the effects of different ligands and mutant enzymes on ∆H and T∆S
(40,41). Finally any proton exchange between enzyme and buffer to which ligand
binding may be coupled could also be perturbed by use of a different mutant and result in
a concomitant change in the thermodynamics of ligand binding. With these caveats in
mind, it is worth noting that all the asymmetric proteins in this series show binding of
DHF to the R67 DHFR•NADP+ complex is enthalpy driven. When trends within an
enzyme variant are considered, most of the binary binding interactions for Quad 3 are
enthalpy driven as are those for the Q67H:1+4 mutant. In contrast, binding in the other
mutants is driven by both thermodynamic components (enthalpy and entropy).
Calderone & Williams (42) suggest structural tightness displays a positive
correlation with the exothermicity of the binding interaction. Maintaining enthalpydriven formation of the ternary complex in these Q67H asymmetric mutants suggests a
strong role for enthalpy in catalysis. Our studies support recent reports of catalytic
function that suggest a strong role for enthalpy (43-51).
To conclude, formation of the R67 DHFR•DHF•NADP+ ternary complex is
enthalpy driven, and introduction of Q67H mutations does not drastically affect its
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Figure 6. A plot of entropy (T∆S) versus enthalpy (∆H) for various mutants and
ligands. Binding data from Quad 3, Q67H:1, Q67H:1+2, Q67H:1+3, Q67H:1+4,
Q67H:1+2+3 and the Q67H homotetramer proteins (1) are included. Values for binding
the first and second NADPH molecules are given by { and gray filled circles. Values
for binding the first and second DHF molecules are given by and gray filled squares.
Values for binding NADP+ are shown by Ì and values for DHF binding to R67
DHFR•NADP+ are given by g points. The slope of the line is 0.85 and the correlation
coefficient is 0.87. A plot of ∆H versus ∆G shows no correlation (not shown).
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formation. This result suggests a strong role for interligand (NADP+ to DHF)
interactions in complex formation. (Presumably interligand interactions would be
important in the NADPH•DHF complex as well). Further, addition of increasing
numbers of Q67H mutations results in the inability of the enzyme to discriminate
between the productive and nonproductive complexes. These results support a role for
Q67 in minimizing formation of the NADPH•NADPH and DHF•DHF complexes.
The Q67H:1+4 double mutant remains an interesting mutant as it displays
minimal NADPH and DHF inhibition and it tightly binds the productive ternary complex
(∆H in table 5 as well as maintains its kcat/Km (NADPH) value). This mutant may serve as a
stepping stone for addition of other asymmetric mutations, leading to design of an
alternate active site constellation with half the pore preferentially binding DHF and the
other half binding NADPH. Further, we anticipate addition of asymmetric mutations at
positions further away from the 222 symmetry operator will allow ready analysis of their
effects as these substitutions will not be involved in the pairwise interactions that occur at
the unusual position at the center of the pore.
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Figure 7. Steady state kinetic data for Q67H:1+3 (top panel) and Q67H:1+4
R67 DHFRs (bottom panel). Nonlinear fitting to equation 1 was performed
using SAS and Table 1 gives the best fit values. Data points above and
below the calculated 3D plot are filled and hollow stars respectively. Kd
values derived from ITC data were used as constraints in fitting with 2-3 fold
variations accepted if the ITC data could be reasonably refit with these
values.
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Figure 8. A series of fluorescence titration curves monitoring the equilibrium
between “open” and “closed” forms of Quad 3 and its mutants. This equilibrium
corresponds to titration of H62 residues. In wt R67 DHFR, titration of H62 is
linked to a tetramer to 2 dimers equilibrium (11-12). Fluorescence data were
converted to a fraction to aid comparison. The points and solid line
correspond to the Quad 3 protein; the ∆ points and the dashed line correspond to
the Q67H:1 mutant; the { points and dotted line correspond to the Q67H:1+2
double mutant. The other 4 proteins are not shown for clarity. Best fit pKa
values associated with the titrations are given in the Table 6.
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Table 6. A comparison of pKa values describing titration of Quad 3 variants from a
“closed” to an “open” form as monitored by fluorescence.

a

DHFR Variant

pKa

Quad 1a

5.5

Quad 3

5.74 ± 0.01

Q67H:1

5.92 ± 0.02

Q67H:1+2

6.22 ± 0.02

Q67H:1+3

6.02 ± 0.03

Q67H:1+4

6.00 ± 0.02

Q67H:1+2+3

6.11 ± 0.03

Q67H:1+2+3+4

6.06 ± 0.07

Value from reference 12.
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Part III: Determining the Role of Symmetry Related Y69 Residues in Ligand
Binding and Catalysis in R67 Dihydrofolate Reductase
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Abstract
R67 dihydrofolate reductase reduces dihydrofolate to tetrahydrofolate where the
cofactor, NADPH, is required for the hydride transfer reaction. The homotetrameric
enzyme provides a unique environment for catalysis as both ligands bind within a single
active site pore. Mutation of one active site residue results in concurrent mutation of
three additional symmetry related residues, and large effects on binding of both ligands as
well as catalysis. For example, mutation of symmetry related tyrosine 69 to
phenylalanine (Y69F), results in large increases in Km values for both ligands and a two
fold rise in the kcat for the reaction [Strader, M. B. et al. (2001) Biochemistry 40, 1134411352]. To understand the interactions between specific Y69 residues and each ligand,
asymmetric Y69F mutants were generated which contain one, two, three, or four Y69F
mutations. A general trend observed from isothermal titration calorimetry and steadystate kinetic studies of these asymmetric mutants is that increasing the number of Y69F
mutations results in an increase in the Kd and Km values. In addition, a comparison of
steady state kinetic values suggests that two Y69 residues on one side of the active site
pore are necessary for NADPH to exhibit a wild-type Km value. A tyrosine 69 to leucine
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(Y69L) R67 DHFR homotetrameric mutant was also generated to approach the type(s) of
interaction(s) occurring between Y69 residues and the ligands. These studies suggest that
the hydroxyl group of Y69 is important for interactions with NADPH while both the
hydroxyl group and benzene ring of the Y69 residues are necessary for proper
interactions with dihydrofolate.
Introduction
Dihydrofolate reductase (DHFR) catalyzes the reduction of dihydrofolate (DHF)
to tetrahydrofolate (THF) via hydride transfer from its cofactor NADPH. DHFR is
necessary for cell survival as THF is involved in pathways leading to the synthesis of
purine nucleosides and other metabolites (1). The chromosomal (E. coli) form of DHFR
is inhibited by trimethoprim. However, R67 DHFR, a plasmid encoded DHFR, has been
found to provides resistance to the antibiotic ((2) and references therein). The plasmid
encoded DHFR is unique in that it shows no structural (3, 4) or genetic (2) homology to
chromosomal DHFR.
R67 DHFR1, shown in Figure 1, is composed of four identical monomers that
associate to form the apoenzyme. Each monomer is made up of 78 amino acids that form
five β-barrel strands oriented antiparallel to one another. The tetramer is classified as a
D2 symmetric enzyme that possesses 222 symmetry (3). Crystallographic data have
indicated that a pore, 25 Å long, extends through the center of the enzyme. The size of
1

The monomers of R67 DHFR are labeled ABDC going in a clockwise orientation in the
crystal structure (1VIE and 1VIF in the Protein Data Bank). The residues in monomer A
are labeled 1-78, while those in monomers B, C, and D are designated 101-178, 201-278,
and 301-378, respectively. All four symmetry related residues are implied when one
residue of the homotetramer is described. The corresponding domains in Quad 3 are
relabeled 1234.
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Figure 1. A ribbon structure of R67 DHFR (protein data bank file 1VIE). Panel A
shows a front view of the R67 DHFR structure, where the active site pore
corresponds to the “doughnut hole” in the center. Monomers are relabeled clockwise
as 1, 2, 3, and 4 (green, yellow, magenta and cyan) respectively. Each monomer
corresponds to a domain in the Quad 3 construct. The protein crystallized had its 16
N-terminal residues removed by chymotrypsin treatment (2, 21). Y69 residues are
indicated by CPK surfaces. Panels B-D illustrate the topologies associated with the
various double mutants. These views are related to that in panel A by a 90o rotation
along the y-axis. Wild-type Y69 residues are shown as CPK surfaces while Y69F
mutants are shown as ball-and-stick structures. Panels B and D represent the Y69F:
1+2 and Y69F: 1+4 mutants where each half of the pore contains one Y69 and one
Y69F residue. Panel C shows the Y69F: 1+3 mutant where one half of the pore
contains two 69 residues and one half of the pore contains two Y69F residues. Panel
E shows a reverse image of the active site pore generated by DOCK (13, 24-25).
Each white sphere corresponds to a potential atom position used by the docking
program. This sphere cluster was generated from panel A by a 90o rotation around
the x and y axes. The reverse image compares to panels B-D by a 90o rotation along
the x axis. The position of a docked NADPH molecule that meets the NMR
constraints is shown in red and the position of the highest scoring docked folate
molecule is shown in orange (13). Stacking between the nicotinamide ring of
cofactor and pteridine ring of folate is predicted near the center of the pore. The
positions of the 4 symmetry related Y69 residues in the surrounding protein are
colored and numbered as described above. The rest of the protein is not shown for
simplicity.
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the pore decreases towards the center of the enzyme due to interactions between
symmetrically related glutamine residues (Q67). Hydrogen bonding interactions between
these residues to create “a floor and ceiling” in the pore and a proposed area for binding
of substrate (DHF)2 and cofactor (NADPH) (3).
In addition to the structure for the apoenzyme, a crystal structure for a binary
enzyme-folate complex has also been solved (3). In this crystal structure, the largest
accumulation of electron density for folate is observed near the pore’s center. This
electron density is most consistent with two folate molecules binding in the pore in
slightly different orientations. Specifically, FolI is proposed to bind in the pore in an
orientation where its si face is available for hydride transfer from NADPH. In contrast,
FolII is bound such that its si face cannot be accessed (3). NMR studies previously
conducted on a variant of R388 DHFR, a homolog of R67 DHFR, indicate that the pro-R
hydrogen is transferred from NADPH to the same face of DHF during the reaction (5).
Thus, only FolI is in the proper orientation to accept a hydride during catalysis (3).
In contrast to folate, attempts at generating co-crystals for NADPH or NADP+
have to date proven unsuccessful. However, NMR studies indicate that the nicotinamide
of the cofactor also interacts with the pteridine ring of folate in the pore’s center as

2

Abbreviations: DHFR, dihydrofolate reductase; TMP, trimethoprim; DHF,
dihydrofolate; THF, tetrahydrofolate; NMNH, reduced nicotinamide mononucleotide;
NADP(+/H), oxidized/reduced nicotinamide adenine dinucleotide phosphate; PABAglutamic acid tail, para-aminobenzoyl glutamic acid region of dihydrofolate/folate; ITC,
isothermal titration calorimetry; CD, circular dichroism; and Quad 3, the protein product
of a tandem array of four in-frame R67 DHFR genes. Mutations are indicated by listing
the wild-type residue and its location in the amino acid sequence followed by the residue
to which it is mutated. For example, mutation of tyrosine at position 69 to phenylalanine
will be represented as Y69F.
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interligand NOEs were observed between NADP+ and a folate analog (6). Chemical
shifts upon ligand binding also suggest that numerous residues comprising the active site
pore are involved in interactions with NADP+ (7).
This present series of experiments examines the means by which NADPH and
DHF interact with R67 DHFR. Since limited structural evidence is available, we have
approached this problem by mutagenesis of specific residues within the active site that
are proposed to facilitate ligand binding and/or catalysis. Site-directed mutagenesis of
most of the residues proposed to comprise the active site surface has been performed (810). Because R67 DHFR is composed of 4 symmetry-related monomers, mutation of one
residue results in 4 symmetry related mutations which often have large effects on kinetic
and thermodynamic parameters (9). Therefore, our goal has been to generate a system by
which we can control the number and location of the mutation(s) by building asymmetric
mutants where only defined subunits of the tetramer are mutated (11, 10, 12). To
approach this goal, Bradrick et al. (12) constructed “quadruple R67 DHFR”. The gene
coding for quadruple R67 DHFR contains four in-frame copies of the DNA encoding
wild-type R67 DHFR. Transcription and translation yield a monomeric protein
mimicking the wild-type protein. Each domain in quadruple R67 DHFR equates to a
monomer in the homotetramer. Unique restriction enzyme sites, flanking the tandem
gene copies, were later engineered into the construct, allowing for removal of the DNA
coding for a specific domain followed by its replacement with DNA containing the
specified mutation(s). Each of the asymmetric mutants described below were generated
in the Quad 3 construct, which has been previously described (11).
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These present experiments explore the role of symmetry related tyrosine 69
residues in ligand binding and catalysis. Docking studies suggest that these symmetry
related residues may play a role in binding both the substrate and cofactor (13). Two
symmetry-related tyrosine 69 residues are proposed to form contacts with the
pyrophosphate bridge of NADPH as well as with the adenine ribose. Docking studies
also predict a possible interaction between the tyrosine hydroxyl and the glutamic acid
tail of folate (13). Kinetic studies of the homotetrameric Y69F mutant also support the
hypothesis that Y69 interacts with both DHF and NADPH, as the Km values for DHF and
NADPH are 11 and 17 fold weaker respectively than those for wild-type R67 DHFR (9).
In addition, the kcat for the reaction is two fold greater than the kcat for wild-type R67
DHFR. These data indicate that although binding of both substrate and cofactor is
weaker, the rate at which the reaction proceeds is faster (9).
Our approach to understanding the role of symmetry related tyrosine 69 residues
in ligand binding and catalysis is two-fold. First, we generated a series of asymmetric
Y69F mutants including a single mutant (containing one Y69F mutation), three double
mutants (each containing two Y69F mutations), a triple mutant (containing three Y69F
mutations), and a quadruple mutant (containing four Y69F mutations) to better
understand the specificity of the interactions between Y69 and both DHF and NADPH.
This approach allows us to determine if there is a preference for NADPH and/or DHF to
interact with wild-type tyrosine 69 residues. Our second approach involved site-directed
mutagenesis of tyrosine 69 residues within the homotetrameric enzyme in order to better
understand the type(s) of interaction(s) occurring between symmetry related tyrosine 69
and the ligands and how these interactions are involved in catalysis.
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Materials and Methods
Construction of asymmetric Y69 mutants:
Asymmetric Y69F mutants were generated by PCR based site-directed mutagenesis as
previously described (11) using the following primer:
Y69F forward: 5′ - GGCTCAGTACAGATCTTCCCTGTTGCGGCG - 3′
Correct mutations were confirmed using ABI Prism Automated Sequencing at the
University of Tennessee DNA sequencing laboratory. DNA containing the appropriate
mutations was transformed into E. coli STBLII cells (14). Cells were grown overnight at
30°C on Luria broth agar plates containing 200 µg/ml ampicillin and 20 µg/ml
trimethoprim to assay for trimethoprim resistance. All six Y69F asymmetric mutants
provided resistance to trimethoprim as evidenced by their ability to allow host E. coli to
grow on LB plates containing 20µg/ml of trimethoprim.
Y69T, Y69K, Y69Q, and Y69L homotetrameric mutants were generated by PCR
based site-directed mutagenesis using the following primers:
Y69T forward: 5′ - GGCTCAGTACAGATCACTCCTGTTGCGGCG - 3′
Y69K forward: 5′ - GGCTCAGTACAGATCAAACCTGTTGCGGCG - 3′
Y69Q forward: 5′ - GGCTCAGTACAGATCCAGCCTGTTGCGGCG - 3′
Y69L forward: 5′ - GGCTCAGTACAGATCCTTCCTGTTGCGGCG - 3′
None of the cell lines transformed with these Y69 mutants were able to grow in the
presence of TMP. Therefore, only the Y69L mutant was pursued.
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Protein expression and purification
For Y69F asymmetric mutant protein expression, STBLII cells were grown at
30°C in TB media (15) containing 200µg/ml ampicillin and 20µg/ml trimethoprim for
approximately 60 hours. Cells were lysed by sonication, and protein was precipitated
with 55% ammonium sulfate. Proteins were purified (as determined by SDS-PAGE)
using a variety of chromatography columns as described previously (1). PEG3350 (0.1g/L)
was added to the buffer to decrease aggregation and is present in most experimental
conditions (16). Extinction coefficients for the asymmetric mutants were determined by
biuret analysis (17).
Steady-state kinetics
Steady-state kinetics were performed for each of the mutants to determine the
corresponding Km and kcat values. Experiments were performed at 30°C on a PerkinElmer Lambda 3B UV/Vis spectrophotometer using UVSL3 software. Experiments were
conducted in MTH buffer (50 mM Mes, 100 mM Tris and 50 mM acetic acid with 10
mM β-mercaptoethanol) at pH 7.0. Data were collected for five sub-saturating
concentrations of NADPH and five sub-saturating concentrations of DHF. The data were
analyzed using SAS as described previously (11) using global, non-linear least squares fit
to a bi-substrate mechanism (18). This software is available on the internet at:
http://www.agriculture.utk.edu/ansci/faculty/saxton_software.html.
Isothermal titration calorimetry (ITC)
Isotherms were generated for substrate or cofactor binding to each asymmetric
mutant on a Microcal VP isothermal titration calorimeter at 28°C. Mes-Tris-acetic acid
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buffer at pH 8 was used for NADPH binding studies while 10 mM Tris + 1 mM EDTA
buffer pH 8 was used for DHF binding studies. As DHF is a weak acid, the pH of the
DHF solution was titrated with NaOH to ~ pH 8 prior to ligand binding studies. The data
for NADPH binding to each of the Y69F asymmetric mutants were analyzed by Origin
software (Version 5.0) using both the single sites model and the sequential sites model
where the stoichiometry was set to two.
Circular dichroism
To determine whether the Y69F asymmetric mutations in Quad 3 and/or the Y69L
mutations in homotetrameric R67 DHFR had affected the overall secondary structure of
the protein, circular dichroism (CD) experiments were performed on an AVIV 202
circular dichroism spectrophotometer at 22°C in phosphate buffer at pH 8. Data were
collected for 10µM protein samples between 190 and 300nm at 2 or 3nm steps (9).
pH titrations
Homotetrameric R67 DHFR dissociates into dimers upon titration with acid due
to protonation of symmetry related histidine 62 residues (19, 20). This dissociation
process can be monitored by a change in fluorescence of symmetry related tryptophan
residues which become solvent exposed upon dissociation of the tetramer (19-21). In
order to determine if Y69L mutations in the homotetramer had affected this equilibrium,
pH versus fluorescence intensity profiles were generated. Data were fit as described
previously by non-linear regression using SAS (9, 19, 20). Although the Y69F
asymmetric mutants are unable to undergo a dimer to tetramer equilibrium as the
domains are covalently linked, it is possible for the domains to “open up” or “splay apart”
upon titration of symmetry related histidine 62 residues (11, 12). This process can also
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be monitored as a change in tryptophan fluorescence as pH is decreased. To determine
whether Y69F asymmetric mutations had affected this process, pH versus fluorescence
intensity profiles were generated. Data were fit to a simple ionization equation using
Sigmaplot (22).
Results
Nomenclature
The following nomenclature will be used to describe each of the asymmetric
mutants. The residue, residue number, and mutation will be listed first followed by a
colon. The asymmetric location of the particular mutations will be indicated numerically
where 1 refers to domain 1, 2 refers to domain 2, etc. This is illustrated using the crystal
structure for homotetrameric R67 DHFR in Figure 1 where each monomer would
correspond to a domain in Quad 3 (3, 23) The four domains are labeled in a clockwise
fashion where domain 1 is located at the bottom, left position. For example, the Y69F:
1+3 mutant contains two mutations: tyrosine 69 in domain 1 has been mutated to a
phenylalanine residue, as has tyrosine 69 located in domain 3. Figure 1 also compares
the different topologies of the three double mutants. For the Y69F: 1+3 mutant, one side
of the pore contains wild-type Y69 residues while the opposite side of the pore contains
mutant Y69F residues (panel C). In contrast, both the Y69F: 1+2 and Y69F: 1+4 mutants
contain one Y69 and one Y69F residue on each side of the pore (panels B and D),
although with different distances between the mutations. Because Y69 residues are
located further away from the center of symmetry, these residues likely interact with the
ADP-ribose and/or the PABA-glutamic acid tails of NADPH and DHF, respectively (3,
13). Figure 1E displays the relative positions of the Y69 residues with respect to a
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docked ternary complex model that incorporates NMR and X-ray crystallography
information (3, 6, 7, 13).
In addition to Y69F asymmetric mutants, the effects of Y69L mutations in the
homotetrameric enzyme were also assessed. This construct will be referred to as Y69L
R67 DHFR and contains four symmetry-related Y69L mutations. For clarity, the data for
the Y69F asymmetric mutants will be discussed first, followed by that for Y69L R67
DHFR.
Steady-state kinetics
In order to gain a better understanding of the effects of Y69 mutations on
catalysis, steady-state kinetic data were collected for each of the asymmetric Y69F
mutants. The kinetic results are presented in Table 1. In general, the Km values for
NADPH and DHF as well as the kcat display a trend contingent upon the location and
number of Y69F mutations. A wild-type Km (NADPH) value is observed for both the Y69F:
1 and Y69F: 1+3 mutants, while the Km (NADPH) for the Y69F: 1+2 and Y69F: 1+4 mutants
is ~3-4 fold weaker. The Km (NADPH) for the triple mutant (Y69F: 1+2+3) continues to rise
as does the Km (NADPH) for the quadruple mutant (Y69F: 1+2+3+4). The kinetic
parameters for the Y69F: 1+2+3+4 mutant are similar to those for Y69F R67 DHFR.
Thus, for NADPH binding interactions in the productive, ternary complex, as the number
of mutations is increased, Km (NADPH) is increased. The two exceptions to this trend are
the Y69F: 1 and Y69F: 1+3 mutants. However, these two mutants are similar in that they
are the only mutants in which an entire “side” of the pore is wild-type. This suggests that
for NADPH to bind in a manner similar to that of the wild-type enzyme, it is necessary
for one side or half of the pore to remain wild-type.
102

Table 1. A comparison of kinetic parameters for wild-type R67 DHFR, Quad 3 DHFR,
Y69F asymmetric mutants, Y69L R67 DHFR, and Y69F R67 DHFR at pH 7.0.

WT R67 DHFRa

kcat
(sec-1)
1.3 ± 0.073

Km (NADPH)
(µM)
3.0 ± 0.060

Km (DHF)
(µM)
5.8 ± 0.015

Quad 3 DHFRb

0.81 ± 0.02

4.4 ± 0.4

6.7 ± 0.4

Y69F: 1 DHFR

0.98 ± 0.06

6.4 ± 0.6

21 ± 2

Y69F: 1+2 DHFR

0.96 ± 0.01

14 ± 0.8

20 ± 0.9

Y69F: 1+3 DHFR

0.56 ± 0.01

3.1 ± 0.4

20 ± 2

Y69F: 1+4 DHFR

1.9 ± 0.08

14 ± 0.7

28 ± 2

Y69F: 1+2+3 DHFR

1.4 ± 0.04

21 ± 0.9

35 ± 2

Y69F: 1+2+3+4 DHFR

1.4 ± 0.04

40 ± 3

54 ± 3

Y69F R67 DHFRc

2.9 ± 0.1

69 ± 3

68 ± 4

Y69L R67 DHFR

0.16 ± 0.01

68 ± 3

180 ±11

Enzyme Variant

a

Taken from (23).
Taken from (11).
c
Refit from (9) using the non-linear, global SAS fit described in (11).

b
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Similar to NADPH interactions in the ternary complex, Km (DHF) values also tend
to increase as the number of mutations is increased. Specifically, the Km (DHF) for the
single and all the double mutants is ~2-3 fold weaker than the Km (DHF) for Quad 3. In
addition, the Km (DHF) for the Y69F: 1+2+3 mutant continues the trend of increasing as
additional mutations are added, up to the limit associated with the Y69F: 1+2+3+4
mutant.
Although binding of both NADPH and DHF in the Michaelis complex is, in
general, weakened as the number of Y69F mutations is increased, the kcat value is
increased. The kcat values vary over an approximately 2 fold range. A trend is noted
where the kcat increases when two Y69F mutations occur in either the “ceiling” and or the
“floor” of the active site pore as occurs in the Y69F: 1+4, Y69F: 1+2+3 and Y69F:
1+2+3+4 mutants, suggesting this topology may be preferred in the transition state.
Isothermal titration calorimetry
Although steady-state kinetics provide important insight into interactions between
ligands in the Michaelis complex, these Km values do not necessarily correspond to
dissociation constants (Kds) as other events can contribute to the observed Km values
(22). Isothermal titration calorimetry provides a direct measure of the heat exchange
upon ligand binding as well as a direct measure of the dissociation constant for the ligand
of interest (26, 27). In order to determine the effects of the asymmetric Y69F mutations
on NADPH and DHF binding, isothermal titration calorimetry experiments were
performed for the binary complexes where either two NADPH molecules or two DHF
molecules interact with the enzyme. Data for NADPH binding to the Y69F asymmetric
mutants are summarized in Table 2. These data were analyzed using both the single sites
104

Table 2. Comparison of NADPH binding constants for Y69F asymmetric mutants and
Y69L R67 DHFR as determined by isothermal titration calorimetry. Data reported were
fit using the single sites model. Each value is an average of at least two different
experiments (except Y69F R67 DHFR).
Kd (µM)

∆H (cal/mol)

Stoichiometry

Quad 3 DHFR

8 ± 0.3

-7600 ± 260

0.83 ± 0.01

Y69F: 1 DHFR

10 ± 1

-6200 ± 120

0.88 ± 0.003

Y69F: 1+2 DHFR

25 ± 2

-4900 ± 170

0.69 ± 0.02

Y69F: 1+3 DHFR

15 ± 1

-5200 ± 390

0.72 ± 0.01

Y69F: 1+4 DHFR

9±1

-7500 ± 490

0.84 ± 0.02

Y69F: 1+2+3 DHFR

25± 2

-5000 ± 120

0.75 ± 0.03

Y69F: 1+2+3+4 DHFR

52 ± 5

-2400 ± 210

0.95 ± 0.11

Y69F R67 DHFRa

65 ± 6

-2200 ± 170

1.1 ± 0.1

Y69L R67 DHFR

75 ± 0.4

-2800 ± 40

1.1 ± 0.1

Complex

a

Refit from (9) to a single sites model.
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model and the sequential sites model where the stoichiometry was set to two. The Kd and
∆H values for the first NADPH binding event were similar regardless of the model used
to describe the data. However the Kd2 and ∆H2 values generated using the sequential sites
model varied, most likely since the Kd2 values are high and fall outside of the detection
window afforded by the calorimeter. For accurate results, the c value, where c is defined
as [protein]*Ka, should occur within a range of 1 and 1000 (26, 27). Therefore, only the
values for the first NADPH binding event are reported.
In general, the effects of the Y69F mutation(s) on NADPH binding to the single
and double mutants are minor, with the Y69F: 1+2 configuration having the most
dramatic effect. However, as the number of mutations is increased in the triple and
quadruple mutants, the Kd values also increase. The enthalpy change for NADPH
binding to the Y69F: 1 and Y69F: 1+4 mutants is similar to that for Quad 3, while the ∆H
becomes less negative as the number of mutations is increased in the Y69F: 1+2+3 and
Y69F: 1+2+3+4 mutants.
Isothermal titration calorimetry experiments were also performed to determine the
effects of asymmetric Y69F mutations on interactions with DHF. Previously, isotherms
generated for DHF binding to wild-type R67 DHFR were fit to an interacting sites model
as isotherms displayed a hook reflecting positive cooperativity between bound DHF
molecules (28). New calorimeters have increased sensitivity to minor changes in solution
pH during the titration. Close attention to the pH of both the ligand and protein solution
indicated that the prominence of the hook is related to changes in pH of the protein
solution upon injection of ligand into the solution. Additional studies indicate that the
presence of the hook is affected by the ionic strength of the buffering solution (data not
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shown). This effect is likely due to disruption of electrostatic interactions between
symmetry related lysine 32 residues and DHF (8). The sensitivity of DHF binding to R67
DHFR may also be related to previous NMR studies that found DHF dimerizes in
solution and this dimerization is affected by ligand concentration (where dissociation
constants for dimerization are in the mM range), pH as well as ionic strength (29, 30).
Due to the characteristics of the isotherms generated for DHF binding to the Y69F
asymmetric mutants, we are unable to consistently fit the data using the Origin software
provided by MicroCal. In particular, if there are only a few points in the hook, the Origin
software does not provide a strong weighting to those points and the fit line does not go
through them. Therefore, for comparative purposes, we have overlaid the raw data for
DHF binding to each of the asymmetric mutants in Figure 2. Based on the raw data, a
trend is observed in both the shape of the curve and the initial heat released upon ligand
binding as well as in the prominence of the hook. Specifically, there appears to be a
trend in the DHF concentration required to reach saturation for the asymmetric mutants.
The signal for Quad 3 increases most dramatically as the DHF concentration is increased;
this behavior is expected when tight binding occurs. The steepness of the slope in the
titrations decreases as the number of mutations is increased. This suggests that as the
number of mutations is increased, more ligand is required to reach saturation and thus
binding interactions are weaker. In addition, the enthalpy change upon ligand binding
appears to decrease from ~ -9000 cal/mole for Quad 3 to ~ -6000 cal/mole for the Y69F:
1+2+3+4 mutant. Finally, an increase in the prominence of the “hook” in the isotherms is

107

Figure 2. Isotherms for DHF binding to Y69F asymmetric mutants generated by
isothermal titration calorimetry. Data for Quad 3 (○), Y69F: 1 (□), Y69F: 1+2 (∆),
Y69F: 1+3 (∇), Y69F: 1+4 (◊), Y69F: 1+2+3 (hexagon), and Y69F: 1+2+3+4 (circle
with dot) mutants are overlaid for comparative purposes.
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observed as the number of mutations increases, with Quad 3 displaying a minimal hook
and the Y69F: 1+2+3 and Y69F 1+2+3+4 mutants displaying the most dramatic hooks.
Physical studies
One possible effect of engineered mutations is a change in protein conformation.
Therefore, circular dichroism spectroscopy was used to determine whether Y69F
asymmetric mutations cause major secondary structural changes in the Quad 3 construct.
As shown in Figure 3, slight to moderate variations in the CD signals are observed for the
Y69F asymmetric mutants and are in the range of those previously observed for other
mutants (9, 11). It seems most likely these variations are due to minor changes in local
protein structure and/or to effects of aromatic residues on the CD signal (9, 11, 31).
Additionally, pH titrations were performed to determine whether the Y69F
asymmetric mutations affected the structure by altering the transition between the “open”
and “closed” conformations of Quad 3 mutants. This equilibrium describes protonation
of symmetry-related histidine 62 residues upon titration with acid (19, 20). As the
proteins are titrated with acid, symmetry-related tryptophan residues become solvent
exposed allowing the pKa for histidine-62 residues to be determined from the titration
(11, 19-21). Figure 4 shows an overlay of several representative titrations for the Y69F
aymmetric mutants. The pKa values for each of the Y69F asymmetric mutants are shown
in Table 3 and are within 0.09 pH units of each other, consistent with minimal structural
perturbations.
Homotetrameric Y69L R67 DHFR
In order to gain a better understanding of the type(s) of interaction(s) formed
between Y69 and the ligands, DHF and NADPH, site-directed mutagenesis of
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Figure 3. Comparison of CD spectra for Y69 mutants. Wild-type R67 DHFR (solid
circle with line through circle), Quad 3 (solid line), Y69F: 1 DHFR (long dash), Y69F:
1+2 DFHR (dotted), Y69F: 1+3 DHFR (medium dash), Y69F: 1+4 (short dash), Y69F:
1+2+3 DHFR (dash-single dot), Y69F: 1+2+3+4 DHFR (dash-two dots), and Y69L
R67 DHFR (solid triangle with line through triangle) spectra are overlaid for
comparative purposes.
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Figure 4. pH titrations for select Y69F asymmetric mutants. Data are plotted as pH
versus Fapparent. Actual data are indicated with symbols while lines through the data
represent the best fit line through the data when H=3 (three his62 residues are
protonated causing the protein to splay open). Quad 3 data (∆) and best fit line (short
dash), the Y69F:1 data (•) and best fit line (solid line), Y69F: 1+2 data (Ο) and best fit
line (dotted), Y69F: 1+4 data (□) and best fit line (dash-dot), and Y69F: 1+2+3 data
(▼) and best fit line (medium dash) are overlaid as representative examples of titrations
for the Y69F asymmetric mutants.
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Table 3. Comparison of pKa values for Y69F asymmetric mutants. Values represent the
pKa of symmetry-related his62 residues which become protonated upon titration with
acid.
Complex

pKa

Quad3 DHFRa

5.74 ± 0.01

Y69F: 1 DHFR

5.73 ± 0.01

Y69F: 1+2 DHFR

5.73 ± 0.01

Y69F: 1+3 DHFR

5.75 ± 0.01

Y69F: 1+4 DHFR

5.78 ± 0.01

Y69F: 1+2+3 DHFR

5.74 ± 0.01

Y69F: 1+2+3+4 DHFR

5.81 ± 0.01

a

Taken from (11)
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homotetrameric Y69 to alternative residues including leucine, lysine, threonine, and
glutamine was performed. These mutations all resulted in the same phenotype (TMP
sensitive host E. coli cells), therefore only one mutant, Y69L R67 DHFR, was further
characterized.
Similar to the effects of Y69F mutations in homotetrameric R67 DHFR (9),
mutation of symmetry related tyrosine 69 residues to non-conservative leucine residues
also affects both ligand binding and catalysis. As indicated in Table 1, the Km (NADPH)
values are similar between Y69F and Y69L R67 DHFRs as are the Kd (NADPH) values
shown in Table 2. In contrast, the Km (DHF) value is ~2.5 fold weaker for Y69L as
compared to Y69F R67 DHFR. In addition, a clear reduction in kcat for Y69L R67 DHFR
is observed as compared to both Y69F R67 DHFR and wild-type R67 DHFR.
Circular dichroism studies, shown in Figure 3, were again performed to ensure
that the Y69L mutations do not cause a large change in the protein structure. Although
changes in the CD signal for Y69L and wild-type R67 DHFRs are observed, these
variations are similar to those observed previously for mutations in the homotetrameric
enzyme and are likely due to local changes in structure brought about by the nonconservative mutations (9).
Titrations of Y69L R67 DHFR with hydrochloric acid were also performed to
ensure that the mutations do not affect the dimer-tetramer equilibrium that occurs upon
protonation of symmetry-related histidine 62 residues (19, 20). The Koverall value
(defined as Kd2n/Ka) for Y69L R67 DHFR differs from that of the wild-type enzyme (data
not shown) suggesting that mutations do have an affect on this equilibrium.
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Discussion
This study investigates the role of Y69 in the binding and catalysis of R67 DHFR.
Since specific contacts involving Y69 with the ligands have not been delineated by NMR
and X-ray crystallography, a mutagenesis approach was used.
Steady-state kinetic and isothermal titration calorimetry studies were performed
on the various Y69F asymmetric mutants. Previous studies suggest that R67 DHFR
follows a random mechanism, but because of the interligand cooperativity patterns,
NADPH binding followed by DHF binding is the preferred pathway (28). Therefore,
when possible, NADPH should bind the enzyme first and preferentially interact with the
tightest binding site available. This site, presumably, should contain the wild-type Y69
residue(s). DHF should bind next to the enzyme•NADPH complex and its pterin ring
would be expected to stack with the nicotinamide ring of NADPH in the center of the
pore. The PABA-glutamic acid tail would then be forced to interact with the amino acid
residue available at position 69, either wild-type or mutant, depending on the
configuration.
NADPH Binding Interactions in the Binary and Michaelis Complexes
Comparisons of steady-state kinetic values for the asymmetric Y69F mutants
suggest that for NADPH to display a wild-type Km value, two Y69 residues are required
and these two residues must be located on the same side of the pore. Only two of the
Y69F asymmetric mutants meet this criterion: Y69F: 1 and Y69F: 1+3. For these
mutants, NADPH likely continues to bind first and prefers the wild-type side of the pore,
thus exhibiting a wild-type Km value as indicated in Table 1. However, when one half of
the pore contains one Y69 and one Y69F residue (Y69F: 1+2, Y69F: 1+4, and Y69F:
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1+2+3), the Km for NADPH might be expected to be weaker if one Y69-NADPH
interaction has been disrupted. As shown in Table 1, the Km (NADPH) values for the Y69F:
1+2 and Y69F: 1+4 mutants are increased 3 fold while the Km (NADPH) value for the Y69F:
1+2+3 mutant is increased 5 fold. This latter increase may be a kinetic effect due to
interligand interactions between NADPH and DHF in the Michaelis complex as DHF
presumably binds to the half pore possessing two Y69F mutations. Finally, the Km
(NADPH) value

for Y69F: 1+2+3+4 continues to increase and mimics the Km (NADPH) for

homotetrameric Y69F R67 DHFR.
Why is it necessary that both tyrosine 69 residues be located on one side of the
pore for NADPH to bind with a wild-type Km? One possibility is that two tyrosine 69
residues located in different domains on the same side of the pore form interactions with
NADPH. Support for this proposal comes from a computational model of the ternary
complex. From this model, contacts are proposed between Y69 in monomer A of the
homotetramer and the pyrophosphate bridge of NADPH as well as contacts between Y69
in monomer D of the homotetramer and the adenine ribose of NADPH (3). Monomer A
corresponds to domain 1 of the Quad 3 construct while monomer D corresponds to
domain 3. As illustrated in Figure 1C, both of these residues have been mutated to
phenylalanine residues in the Y69F: 1+3 mutant. However, due to the symmetry of the
protein, the same contacts proposed in the docking model can also occur between Y69
residues in domains 2 and 4 and NADPH.
Since a direct interaction(s) between the -OH of Y69 and NADPH was not
predicted, either the ternary complex model requires revision or water mediated
interactions could be occurring. Alternatively, since the contacts predicted by DOCK
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betweenY69 residues and NADPH largely involve the ring edge of the tyrosine residue
(8), it is possible that a dipole-charge interaction(s) may be present (1/r2 distance
dependence; (32)). Since the phenylalanine sidechain lacks the -OH group of tyrosine,
this dipole moment would be diminished in the Y69F mutant.
Do the Kd data also support the model that suggests two Y69 residues are
involved in NADPH binding? In general, the Kd values for NADPH binding obtained by
ITC correspond to the Km values and exhibit a similar trend in that the Kd values increase
as the number of mutations is increased. The ∆H values also become less negative as the
number of mutations is increased. If the Kd values were to exactly mimic the Km
behavior, the Kd (NADPH) for the Y69F: 1+3 mutant should be wild-type and the Kd (NADPH)
for the Y69F: 1+4 mutant would be weaker. Instead, the Kd and ∆H values for the Y69F:
1+4 mutant are more similar to Quad 3 values than those for the Y69F: 1+3 mutant.
However, some differences may occur as these two techniques monitor different
complexes, the Michaelis complex for steady-state kinetics and a binary complex where
two NADPH molecules bind for isothermal titration calorimetry. Since interactions
between two NADPH molecules versus one DHF and one NADPH molecule are likely
different, it is possible that these differences are reflected in the values obtained by the
two techniques.
DHF binding interactions in the binary and Michaelis complexes
Interligand Overhauser effects suggest that NADPH and DHF bind on opposite
halves of the pore, allowing only the rings of the ligands to interact at the pore’s center
(6). This model is supported by steady-state kinetics data for the Y69F: 1 and Y69F: 1+3
mutants which suggest that NADPH interacts with the wild-type side of the pore, thus
116

forcing DHF to bind to the other half pore which contains a mutation(s). Therefore for
these mutants, a wild-type Km (NADPH) is observed coupled with a weaker Km (DHF) value.
Also, similar Km (DHF) values are observed for the Y69F: 1+2 and Y69F: 1+4 mutants as
both halves of the pore possess a mutation. The Km (DHF) value for Y69F: 1+2+3 is
weaker than that of the single and double mutants as the second half of the pore now
contains two mutations. The Km (DHF) for Y69F: 1+3 is tighter than expected since the
half pore with which DHF is proposed to interact also has two mutated Y69 residues.
However, previous studies suggest the importance of interligand interactions in ligand
binding (28). Specifically, positive cooperativity between enzyme bound NADPH and
the second ligand, DHF, is proposed to facilitate binding of DHF (28). Since NADPH is
proposed to bind in a wild-type orientation in Y69F: 1+3 DHFR, it is possible that
interligand interactions between bound NADPH and DHF partially account for the tighter
Km (DHF) observed in this mutant.
Support for this model is also provided in the ternary complex model where folate
was docked into a DHFR•NMNH complex. (NMNH is a fragment of NADPH that
contains only the nicotinamide ring, ribose ring, and a single phosphate group.) From the
docking studies, the highest scoring folate conformer is predicted to form a hydrogen
bond between the –OH of Y69 (in monomer C which corresponds to domain 4 of Quad
3) and the α-carboxylate of the folate tail. However, other high scoring folate conformers
are also predicted with alternate positions for the PABA-glutamic acid tail of DHF (13).
Mobility in the tail region has additionally been observed in both X-ray crystallography
and NMR studies (3, 6). It is therefore possible that interactions occurring between Y69
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and folate (or DHF) are weak and/or transient, hence, interligand interactions between
enzyme bound NADPH and folate/DHF play an important role in DHF binding.
Do these trends continue in the DHF binary complex data? Although we are
unable to quantify differences in binding affinity of the Y69F symmetric mutants for
DHF, we can draw qualitative conclusions based on variations in isotherm shape for the
asymmetric mutants. First, increasing the number of Y69F mutations weakens the
binding affinity for DHF as increasing DHF concentrations are required to reach
saturation. Interestingly, as the number of Y69F mutations is increased, a more
prominent hook is observed in the isotherms, suggesting changes in inter-ligand
interactions between the two DHF molecules and/or different enthalpies associated with
the two binding events.
What role does Y69 play in catalysis?
Mutation of tyr 69 to phe in R67 DHFR facilitates catalysis as the kcat value for
the mutant reaction increases (9). Comparison of the kcat values for Quad 3 and the
Y69F: 1+2+3+4 mutant reveals an approximately 2 fold increase in the kcat upon addition
of the mutations. This increase is comparable to the increase observed in Y69F R67
DHFR as compared to wild-type R67 DHFR. That the kcat for the Y69F: 1+2+3+4
mutant is less than that of Y69F R67 DHFR is not unreasonable since the kcat for Quad 3
is also less than the kcat for wild-type R67 DHFR (11). In addition, an increase in kcat is
not observed until two Y69F mutations are present in the Y69F: 1+4 mutant. The kcat
values for the Y69F: 1+2+3 and Y69F: 1+2+3+4 mutants are similar to that of the Y69F:
1+4 mutant indicating that increasing the number of Y69F mutations to 3 or 4 does not
result in additional increases in kcat. These three mutants are similar in that they each
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contain two mutations along either the ceiling and/or floor of the active site pore. It is
therefore tempting to suggest that loss of interactions between these residues and
NADPH and/or DHF facilitate the reaction.
Based on steady-state kinetic analyses of Y69F R67 DHFR and the Y69F
asymmetric mutant series, one possible role for Y69 is in ground-state binding. This is
supported by steady-state kinetic data where the Km values for NADPH and DHF binding
are increased as the number of mutations is increased. However, these data also suggest
that in order to reach the transition state, it is necessary for at least one Y69 interaction to
be disrupted. This is supported by increasing kcat values as Y69 residues are mutated to
phenylalanine in the Y69F: 1+4, Y69F: 1+2+3, and Y69F: 1+2+3+4 mutants. These data
continue to support the model (9) that Y69F mutations in the homotetramer destabilize
binding in the ground state to a greater extent than binding in the transition state. Further,
the model can be extended such that the Y69F: 1+4 double mutant topology appears to
provide the least perturbation to ground-state binding coupled with the best match to the
transition state configuration.
What types of interactions occur between the ligands and Y69?
Another goal of this mutagenesis series has been to determine the type(s) of
interaction(s) that occur between Y69 and both NADPH and DHF. We have approached
this goal via site-directed mutagenesis of symmetry-related Y69 residues to both
conservative and non-conservative amino acid residues. With the exception of the Y69F
enzyme variants, site-directed mutagenesis of Y69 to other amino acid residues has been
complicated by trimethoprim sensitivity in cells containing the mutagenized plasmids.
The importance of Y69 in catalysis is, therefore, emphasized in that most mutations at
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this position are not tolerated without a loss of TMP resistance which usually correlates
with large decreases in protein yield and/or kcat/Km.
Comparisons of the kinetic parameters observed for Y69F R67 DHFR, Y69L
R67 DHFR, and wild-type R67 DHFR yield interesting information regarding the
involvement of Y69 in both ligand binding and catalysis. Analysis of Y69F R67 DHFR
suggests the importance of tyrosine’s hydroxyl group as its removal results in a 20 fold
increase in Km (NADPH) and a 10 fold increase in Km (DHF) (9). Hence, the hydroxyl group is
necessary for binding interactions with NADPH and DHF. However, removal of the
hydroxyl group appears to facilitate catalysis as the kcat for Y69F R67 DHFR is increased
~ 2 fold in comparison to the wild-type enzyme (9). Similar to Y69F R67 DHFR, the
steady state kinetic parameters are also affected in Y69L R67 DHFR. The Km (DHF) for
Y69L R67 DHFR is > 20 fold weaker than the Km (DHF) for wild-type R67 DHFR and is
~2.5 fold greater than the Km (DHF) for Y69F R67 DHFR suggesting that the aromatic ring
of Y69 as well as the hydroxyl group are important for interactions with DHF. Although
the Km (NADPH) is also increased in Y69L R67 DHFR as compared to the wild-type
enzyme, the value is similar to that obtained for Y69F R67 DHFR suggesting that the
hydroxyl moiety is most important for interactions with NADPH. This is supported by
the similar Kd values obtained for NADPH binding to Y69L R67 DHFR and Y69F R67
DHFR. The aromatic ring also appears to play an important role in catalysis as is
evidenced by the 4 fold decrease in kcat in Y69L R67 DHFR. Whether the hydroxyl and
aromatic regions of tyrosine 69 are directly involved in interactions with both DHF and
NADPH or are mediated through water is not clear. Direct assessment of the type of
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interaction afforded by tyrosine 69 and the ligands requires more structural based studies
such as NMR and x-ray crystallography, which are currently in progress.
What general trends are observed for Quad 3 asymmetric mutants?
We have previously constructed asymmetric mutant series involving Q67H (1) as
well as K32M substitutions (Hicks et al., manuscript in preparation). From these studies,
as well as the present experiments, several general trends are noted. (K32, Q67, I68 and
Y69 have been identified as the most important residues in binding and catalysis from a
series of site directed mutagenesis experiments probing the residues in the active site pore
((2, 9), Strader et al., manuscript submitted,). The first pattern finds the single
asymmetric mutant behaves similarly to Quad 3, indicating a single mutation is well
tolerated. Conversely, to produce a substantial effect and begin to mimic the mutation in
a homotetrameric context, three mutations are usually required. (This could not be
accomplished with the K32M asymmetric mutants as this mutation affects the dimerdimer interface, hence only single and double K32M mutants were constructed (Hicks et
al., manuscript submitted)). Second, the 1+2 and 1+4 double mutants (Y69F and K32M
series) show similar steady state kinetic behavior. For these mutants, an initial
expectation was that if the docked model for the ternary complex described how the
molecules were arranged in the ground state, then minimal effects on kcat and Km would
be expected for the asymmetric mutant that matches this predicted, productive topology
(1+2), with larger effects on the non-preferred topology (1+4). However the observed
similar kinetic behavior for the 1+2 and 1+4 mutants indicates that both topologies allow
comparable interactions with the PABA-glutamic acid tail of DHF. This behavior
correlates with the disorder observed for the glutamate tail of bound folate in the crystal
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structure (6) as well as NMR studies that find the glu tail is mobile (3). Further, docking
of DHF into an R67 DHFR•NMNH complex predicts various orientations for the paminobenzoic acid (PABA)-glu tail (13).
A third, general pattern observed for the K32M and Y69F asymmetric mutant
series is that the 1+3 double mutants show minimal perturbation of NADPH binding.
This pattern supports initial binding of NADPH into the “wild type half-pore” followed
by DHF being forced to bind in the “mutant side.” Consequently greater effects on DHF
binding are observed in these mutants. Fourth, mutations at the center of the pore
(Q67H) produce different effects than mutations further out on the pore surface (K32M
and Y69F). For example, the Q67H mutations are associated with tighter binding of all
complexes and result in severe NADPH and DHF inhibition. This observation is
consistent with the crystallographic R67 DHFR•folate•folate binary complex and the
docked ternary complex model that point to the hourglass center of the pore being
associated with ring stacking and helping to establish interligand cooperativity patterns.
In contrast, mutations further out the pore surface do not display substrate/cofactor
inhibition, but rather are most consistent with alternative binding modes associated with
the DHF tail being tolerated.
To conclude, these trends all support the general model whereby NADPH and
folate enter the active site pore from either end, meeting at the center where catalysis
occurs. NADPH likely binds first, with a preference for the least perturbed side of the
pore. The nicotinamide ring then provides an interaction surface for binding the pteridine
ring of DHF. A “one site fits both” strategy must be employed because the homotetramer
possesses only a single active site pore coupled with the need to bind two ligands. This
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“catch-22” situation appears to lead to symmetry related residues that aid ligand binding,
but provide too much ground state stabilization. To reach the transition state, some of
these interactions likely need to break. Thus construction of asymmetric mutants has
begun to provide clues to unravel how R67 DHFR works as an enzyme.
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Catalytic Efficiency
R67 dihydrofolate reductase provides a unique approach to catalysis as a 25Å
pore serves as the binding site for both ligands, DHF and NADPH (2). Compared to
other enzymes, however, R67 DHFR is rather inefficient. Enzyme efficiency is defined
by kcat/Km. For the most efficient enzymes, such as acetylcholinesterase, the kcat/Km
values are on the order of 108 s-1M-1(3). In these enzymes, the rate-determining step for
the reaction approximates the rate of encounter of the enzyme and substrate which is
diffusion-limited (3). In contrast, lower kcat/Km(NADPH) and kcat/Km(DHF) values of 1.8•105s1

M-1and 1.2•105 s-1M-1, respectively are observed for R67 DHFR, yielding a less efficient

enzyme (4).
One of the goals of asymmetrically mutating R67 DHFR has been to artificially
generate a more efficient enzyme (5). This goal was first approached by generating
asymmetric Q67H mutants (1). Interestingly, Q67H R67 DHFR is a more efficient
enzyme than wild-type R67 DHFR as its kcat/Km(NADPH) value is 10 fold greater than the
wild-type enzyme, while the kcat/Km(DHF) value is also slightly increased (1.2 fold) (5).
The increase in catalytic efficiency for the Q67H R67 DHFR mutant is largely due to the
increase in binding affinity for both NADPH and DHF (~200 and ~40 fold, respectively)
as the kcat for the reaction actually decreases ~50 fold (5). With this increase in binding
affinity, however, an increase in non-productive binding is observed for Q67H R67
DHFR where both substrate and cofactor become inhibitory (5). Therefore, our goal in
generating the asymmetric Q67H mutants was to generate an efficient enzyme which
maintains tight binding but disfavors formation of inhibitory complexes (1, 5).
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Table 1 compares the kcat/Km values for the Q67H asymmetric mutants. As
indicated in the table, none of the kcat/Km values for the asymmetric mutants is increased
greater than that of the Q67H: 1+2+3+4 asymmetric mutant which corresponds to Q67H
R67 DHFR, except the kcat/Km(NADPH) value for the Q67H:1+2 mutant which is increased
~2 fold compared to the quadruple mutant. The binding and catalysis constants for the
Q67H: 1+2+3+4 mutant are similar to those for Q67H R67 DHFR (1). Unfortunately,
rather noticeable inhibition, similar to that observed for Q67H R67 DHFR, is also
observed for this mutant. Although the Q67H: 1+2 mutant also has an obvious increase
in the kcat/Km(NADPH), cofactor inhibition is noticeable in this mutant as well. The only
Q67H asymmetric mutants which lack clear substrate and/or cofactor inhibition are the
Q67H: 1 and Q67H: 1+4 mutants (1). However, the catalytic efficiency of these mutants
is not increased relative to the Quad 3 control. In fact, the kcat/Km(DHF) values are actually
decreased ~ 2 fold. We were, therefore, unable to engineer a more efficient enzyme
lacking substrate and cofactor inhibition with this series of asymmetric mutants.
One issue associated with the Q67H asymmetric mutants is the location of Q67
residues in the center of the active site pore (1). These residues form the “ceiling” and
“floor” of the pore as they form hydrogen bonds with their symmetry related residues
across the dimer-dimer interface of the enzyme (2). We, therefore, proposed that
introduction of histidine residues asymmetrically at these locations may affect local
packing interactions as the hydrogen bonding network may be disrupted when one
histidine is introduced along the dimer-dimer interface (i.e. in the Q67H: 1+3 mutant) (1).
This problem diminishes when the mutated residues occur further from the center of
symmetry. As shown in Figure 1, symmetry related tyrosine 69 residues occur further
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Table 1. Comparison of catalytic efficiencies for Q67H, Y69F, and K32M asymmetric
mutants of Quad 3 DHFR.
Complex

kcat/Km(NADPH)
(s-1M-1)

kcat/Km(DHF)
(s-1M-1)

Quad3 DHFRa

1.8*105

1.2*105

Q67H: 1 DHFRb

1.8*105

6.0*104

Q67H: 1+2 DHFRb

7.5*105

6.0*104

Q67H: 1+3 DHFRb

1.3*105

2.0*104

Q67H: 1+4 DHFRb

1.6*105

6.0*104

Q67H: 1+2+3 DHFRb

2.0*105

1.0*104

Q67H: 1+2+3+4 DHFRb

3.8*106

7.7*105

Y69F: 1 DHFRc

1.5*105

5.0*104

Y69F: 1+2 DHFRc

7.0*104

5.0*104

Y69F: 1+3 DHFRc

1.8*105

3.0*104

Y69F: 1+4 DHFRc

1.4*105

7.0*104

Y69F: 1+2+3 DHFRc

7.0*104

4.0*104

Y69F: 1+2+3+4 DHFRc

4.0*104

3.0*104

K32M: 1 DHFRa

1.6*105

9.0*104

K32M: 1+2 DHFRa

1.0*104

7.0*104

K32M: 1+3 DHFRa

2.0*104

1.0*104

K32M: 1+4 DHFRa

2.0*104

1.0*104

a

Taken from (Hicks et al., manuscript in preparation).
Taken from (1).
c
Taken from (Stinnett et al., manuscript in preparation).
b
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Figure 1. Ribbon diagram of R67 DHFR (protein data bank 1VIE) with Y69 residues
shown as purple balls-and-sticks, while Q67 residues are shown as white balls-andsticks. Monomer 1 is green, while monomers 2, 3, and 4 are yellow, pink, and cyan,
respectively.
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from the center of symmetry than symmetry related glutamine 67 residues. The tyrosine
69 residues are also sufficiently separated that they are unable to hydrogen bond with
their symmetry related partners (2, 6). In addition, the kcat for the Y69F R67 DHFR
mutant is increased ~2 fold in respect to the wild-type enzyme while the Km(NADPH) and
Km(DHF) values are increased ~15 and ~10 fold, respectively (6). It was, therefore,
possible that a more efficient enzyme could be generated in the Y69F asymmetric mutant
series where the kcat for the reaction is increased but the Km values are unaffected.
Catalytic efficiencies for each of the Y69F asymmetric mutants are outlined in
Table 1. None of the kcat/Km values for these mutants is increased relative to the Quad 3
control. In fact, in most cases, these mutants are less efficient than the Quad 3 control.
This is likely due to the disparate effects of the mutations on both the kcat and Km values.
For example, the Y69F: 1 and Y69F: 1+3 mutants are the only mutants where the
Km(NADPH) values are unaffected. However, for these mutants, the kcat values are also
affected minimally (Stinnett et al., manuscript in preparation). Hence, the kcat/Km(NADPH)
values for these mutants are similar to the Quad 3 control. In addition, the Km(DHF) values
for the remainder of the asymmetric Y69F mutants are weakened in respect to the Quad
3 control, thus resulting in lower kcat/Km(DHF) values (Stinnett et al., manuscript in
preparation). Although it was proposed that a more efficient enzyme could be generated
where the Km values were unaffected and the kcat values were increased, for the Y69F
asymmetric mutant series, an increase in kcat was observed only when Km values were
also increased (Stinnett et al., manuscript in preparation). Therefore, none of the Y69F
asymmetric mutants were more efficient enzymes than the Quad 3 control.
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Asymmetric mutants of symmetry related K32 residues have also been generated
and analyzed (Hicks et al., manuscript in preparation). Similar to Y69, K32 residues are
also located further away from the center of symmetry of the active site (2). In contrast
to Y69, however, mutation of K32 residues to methionine residues in the homotetrameric
enzyme results in a dimeric form of the enzyme (7). Since docking studies suggest that
these residues interact with both ligands of R67 DHFR (8), an alternate approach
involving salt effects was employed to determine the role of these residues in ligand
binding and catalysis (7).
Lysine residues, being positively charged in water at pH values around neutrality,
are capable of forming ionic contacts with negatively charged ligands which include the
ligands for DHFR. Therefore, it is possible for lysine 32 residues to interact with both
NADPH and DHF electrostatically. Since mutagenesis of K32 residues to non-polar
methionine residues affects the stability of the enzyme, the interactions between K32
residues and the ligands were evaluated by adding increasing concentrations of salt into
the reaction solution. From these studies, it was determined that symmetry related K32
residues are involved in interactions with both NADPH and DHF (7).
Similar to studies of Y69F R67 DHFR, disruption of electrostatic interactions
between symmetry related K32 residues and the substrate and cofactor yields an
increased rate of catalysis for the reaction while resulting in weaker Km values for both
ligands (7). Therefore, generation of a more efficient enzyme could again be possible by
building asymmetric K32M mutants where the Km values are minimally perturbed but kcat
is increased. In addition, it was proposed that adding only one or two K32M mutations to
the enzyme would be less destabilizing than adding all four mutations to the enzyme (as
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occurs in K32M R67 DHFR). Therefore, the following K32M asymmetric mutants were
generated and analyzed: K32M: 1, K32M: 1+2, K32M: 1+3, and K32M: 1+4 (Hicks et
al., manuscript in preparation).
The catalytic efficiencies of each of the K32M asymmetric mutants are shown in
Table 1. The kcat/Km values for the K32M: 1 mutant are similar to Quad 3 as would be
expected since the kcat and Km values are affected minimally in this mutant (Hicks et al.,
manuscript in preparation). Each of the kcat/Km values for the double mutants is
decreased with respect to Quad 3. However, the cause of this decrease differs for the
K32M: 1+2 and K32M: 1+4 mutants as compared to the K32M: 1+3 mutant. For the
K32M: 1+2 and K32M: 1+4 mutants, the decrease in kcat/Km values is largely related to
the effect of these mutations on kcat (Hicks et al., manuscript in preparation). For both
mutants, the rate of the reaction is slower, while the Km values are either not affected or
are increased no more than four-fold (Hicks et al., manuscript in preparation). These
effects combine to yield decreases in kcat/Km. In contrast, the rate of catalysis for the
K32M: 1+3 mutant is increased ~ 4.5 fold. However, the Km values for NADPH and
DHF are increased ~ 35 fold and ~50 fold, respectively. Although an increase in kcat is
observed, greater increases in the Km values result in decreases in kcat/Km. Again, in no
K32M asymmetric mutant was the catalytic efficiency increased as none of the mutations
resulted in increasing kcat values with minimal effects on Km (Hicks et al., manuscript in
preparation).
Interestingly, none of our mutagenesis strategies, including mutations in the
homotetramer and asymmetric mutations, has generated a more efficient enzyme that
does not also yield substrate and cofactor inhibition. Is it possible that this enzyme is
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optimized for the greatest possible efficiency without substrate and cofactor inhibition?
While this possibility exists, we have yet to test the effects of generating asymmetric
mutants which contain different amino acid mutations such as asymmetric mutants
containing both Q67H and Y69F or Q67H and K32M mutations.
Why generate mutants with both Q67H and Y69F or K32M asymmetric
mutations? Q67H asymmetric mutations result in decreases in Km values and kcat values
(1), while certain Y69F asymmetric mutations result in increases in Km and kcat values
(Stinnett et al., manuscript in preparation) as does the K32M: 1+3 mutant (Hicks et al.,
manuscript in preparation). It is therefore possible that building an asymmetric mutant
containing both Q67H and Y69F or K32M mutations may result in decreased Km values
and an increase in kcat values yielding a more efficient enzyme.
Of the possible Y69F/Q67H asymmetric mutant combinations, which
combination would likely result in the most efficient enzyme which is not inhibited at
high concentrations of substrate and cofactor? In order to approach this question, it is
first necessary to understand which mutations result in tighter Km values and which
facilitate kcat. A single Q67H mutation results in an ~ 4 fold decrease in kcat with little
affect on the Km values. This effect may be related to disruption of hydrogen bonding
interactions between symmetry-related Q67 residues which could affect local packing
interactions (1). To minimize this possibility, both glutamine residues along one dimerdimer interface should be mutated to histidine residues. This occurs in the Q67H: 1+4
mutant. For this mutant, the Km(NADPH) is ~4.5 fold tighter than the Quad 3 control while
the Km(DHF) is only ~ 2.5 fold tighter than the Quad 3 control. In addition, no noticeable
DHF or NADPH inhibition is observed for this mutant making it an ideal template on
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which to add Y69F mutations (1). Of the Y69F double mutants, only one results in a
noticeable increase in kcat for the reaction, the Y69F: 1+4 mutant. This mutant contains
two Y69F mutations, both located along the “floor” of the active site. It was therefore
proposed that mutation of two Y69 residues along the dimer-dimer interface may
facilitate transition state binding (Stinnett et al., manuscript in preparation). The
Km(NADPH) and Km(DHF) values for this mutant are increased ~2.5 fold and ~ 4 fold,
respectively, while the kcat is increased ~ 2 fold (Stinnett et al., manuscript in
preparation). Based on this information, we propose that the combination of Y69F:
1+4/Q67H: 1+4 mutations may result in a more efficient enzyme (compared to the Quad
3 control) as the Q67H mutations will drive tighter binding and the Y69F mutations will
facilitate catalysis. We also expect that this mutant will not be inhibited at high
concentrations of substrate and cofactor as the Q67H: 1+4 mutation and the Y69F: 1+4
mutation do not cause noticeable DHF and NADPH inhibition ((1), Stinnett et al.,
manuscript in preparation).
What K32M/Q67H asymmetric combinations may increase catalytic efficiency?
In this case, we propose use of the Q67H: 1+2+3+4 mutant as a template as the Km(NADPH)
and Km(DHF) values for this mutant are ~ 170 and ~ 50 fold tighter, respectively, than
those of the Quad 3 control (1). Of the possible K32M asymmetric mutants, we propose
addition of K32M mutations to domains 1 and 3 of the Q67H: 1+2+3+4 template. These
mutations are chosen as they include the only K32M asymmetric mutations which result
in an increase in kcat for the reaction (Hicks et al., manuscript in preparation). For the
Q67H: 1+2+3+4/K32M: 1+3 mutant, we expect that NADPH will bind first to the
enzyme and its nicotinamide ring will interact with the Q67H residues along either the
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“floor” or “ceiling” of the active site. The tail of NADPH will interact with wild-type
K32 residues (in domains 2 and 4) on one half of the enzyme. DHF will bind following
NADPH and interact with both the nicotiname ring (through interligand contacts) and the
residues available on the opposite side of the pore, specifically with the Q67H residues
located on the “floor” or “ceiling” (which are not tied up forming contacts with NADPH).
The kcat for the reaction will be increased as these studies suggest that a K32 interaction
with DHF must be disrupted to approach the transition state, and this requirement is
fulfilled in the K32M: 1+3 mutant where no wild-type K32 residues are available to
interact with DHF (Hicks et al., manuscript in preparation). Therefore, we propose that
generation of a Q67H: 1+2+3+4/K32M: 1+3 mutant may yield an increase in catalytic
efficiency as the Q67H mutations will drive tight binding through ring stacking
interactions while the K32M mutations will facilitate catalysis. Some inhibition,
however, is possible in this construct as noticeable inhibition is observed for the Q67H:
1+2+3+4 mutant (1, 5).
Ligand Specificity
In addition to attempts at generating a more efficient enzyme, another goal of
building asymmetric mutants is to engineer specificity into the active site such that
NADPH and DHF each bind at a specific location rather than having the option of
interacting at four positions (1). Steady-state kinetic analyses of certain Y69F (Stinnett et
al., manuscript in preparation) and K32M (Hicks et al., manuscript submitted)
asymmetric mutants suggest that this has been accomplished for NADPH. For the Y69F:
1 and Y69F: 1+3 mutants, a wild-type Km(NADPH) value is observed while a weaker
Km(DHF) occurs (Stinnett et al., manuscript in preparation). In addition, the Kd(NADPH) for
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the K32M: 1 and K32M: 1+3 mutants is affected to a lesser extent by the mutations than
the K32M: 1+2 and K32M: 1+4 mutants (Hicks et al., manuscript in preparation). These
data suggest that NADPH interacts first with the enzyme preferentially forming contacts
with the wild-type side of the pore. DHF then interacts with the residues available on the
other side of the pore (Stinnett et al., manuscript in preparation, Hicks et al., manuscript
in preparation). This is supported by the Q67H asymmetric mutant studies. In these
studies, four Q67H mutations were necessary to yield a greater than 3 fold decrease in the
Km(DHF) value (1).
Although evidence suggests that NADPH binding specificity has been engineered
into the enzyme through generation of certain asymmetric Y69F and K32M mutants,
DHF specificity has not been achieved as DHF interacts with the site available following
NAPDH binding. Weaker Km(DHF) values have therefore been observed as DHF is
required to interact with a least one mutant residue on the opposite side of the active site
pore (Stinnett et al., manuscript in preparation, Hicks et al., manuscript in preparation).
How then can DHF specificity be engineered into R67 DHFR? Can we “rescue” DHF
binding by engineering the opposite side of the pore with residues that will drive DHF
binding.
One possible means to generate DHF specificity is to again build asymmetric
mutants which contain mutations of different amino acid residues such as K32 and Y69.
Structural based studies, including NMR and x-ray crystallography, as well as docking
studies, predict mobility of the glutamic acid tail of DHF/folate (2, 8, 9). In addition,
studies involving asymmetric K32M (Hicks et al., manuscript in preparation) and Y69F
(Stinnett et al., manuscript in preparation) mutants suggest that interactions between these
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residues on one side of the pore are weak allowing mobility of the tail between both
domains. One means to provide greater specificity for DHF would therefore be to
provide additional contacts for the DHF tail on a single domain of one half of the active
site limiting mobility of the tail region. Several studies also suggest that NADPH may
participate in DHF binding through interligand interactions (9, 10). Thus, optimal DHF
binding would be provided by tight binding of the nicotinamide ring of NADPH which,
through interligand interactions, may tighten DHF binding. In addition, specificity for
DHF binding may be generated by providing additional contacts to the tail of DHF.
What asymmetric mutations could tighten NADPH binding and through
interligand contacts tighten DHF binding while providing contacts with the tail of DHF to
limit its mobility? The Q67H: 1+4 mutant provides a tighter binding site for NADPH
which likely tightens DHF binding through interligand interactions (1). Therefore, this
mutant may provide a template for addition of other mutations to provide specificity for
DHF (1). Additional mutations must be built into this construct which preferentially
provide contacts with the tail of DHF in contrast to the tail of NADPH. Mutation of a
Y69 residue to a lysine residue may provide such a contact. Docking studies suggest that
a hydrogen bond may form between the hydroxyl group of tyrosine 69 in domain 4 and
the glutamate tail of DHF (8) which could, in theory, be replaced by ionic interactions
between a lysine residue and the glutamate tail. However, most contacts proposed
between Y69 and NADPH are through the ring edge of tyrosine (8). Mutation of the
residue to lysine would result in disruption of these interactions. Therefore, a Q67H:
1+4/Y69K: 4 mutant could provide tight binding of NADPH through ring stacking
interactions between the histidine residues and the nicotinamide ring. Interligand
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interactions between NADPH and DHF would facilitate DHF binding. In addition, the
tail of DHF should interact preferentially with the Y69K residue in domain 4 thereby
limiting its mobility and rendering greater affinity. The tail of NADPH would be
disfavored from interacting with this residue as it lacks the ring edge dipolar contacts
provided by the tyrosine residue (Stinnett et al., manuscript in preparation).
Selection of the Productive Ternary Complex
Another aspect of ligand binding in R67 DHFR that has become apparent through
studies of these asymmetric mutants is the ability or inability of certain mutants to select
for the productive ternary complex over the non-productive 2NADPH/2DHF binding
modes. Of the asymmetric mutants that have been analyzed, one series of mutants is
particularly limited in its ability to select for the productive ternary complex, the Q67H
series (1). While moderate to severe substrate and/or cofactor inhibition is observed for
most of the Q67H asymmetric mutants (1), no DHF and/or NADPH inhibition has been
observed for any of the other asymmetric mutants (Stinnett et al., manuscript in
preparation, Hicks et al., manuscript in preparation). What characteristics of these
mutants render them unable to select for the productive ternary complex?
In contrast to Y69 and K32, Q67 residues are located in the center of the active
site pore (2) allowing them to form contacts with the pteridine ring of DHF (2) and the
nicotinamide ring of NADPH (9) which are also proposed to interact in the pore’s center.
Mutation of these residues to histidine residues tightens binding for each ligand of R67
DHFR (1, 5). It has been suggested that this increase in binding affinity is related to
stacking interactions between the rings of symmetry related histidine side chains and both
the pteridine and nicotinamide rings (1, 5). Structural evidence also suggests that the
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NADPH and DHF tails are pointed away from the center of the enzyme’s active site.
Thus, interligand interactions between DHF and NADPH occur mainly between the
pteridine and nicotinamide rings. Q67H mutations increase the binding affinity for both
DHF and NADPH (9). This increase in binding affinity likely alters the interligand
cooperativity patterns between the 2DHF and 2NADPH non-productive binding modes in
addition to the interligand interactions between the productive binding mode.
Specifically, the productive binding mode has been altered in these mutants as the kcat for
the reaction decreases as the number of mutations is increased. This suggests that the
nicotinamide and/or pteridine ring orientations are altered to some extent in these mutants
as a result of ring stacking interactions. As the rings must be juxtaposed in an optimal
orientation for hydride transfer, it is likely that interactions with the histidine residues
alter this juxtaposition (1). It has been proposed that the nicotinamide and pteridine rings
of R67 DHF are likely oriented in an endo conformation in the transition state (9). These
ring stacking interactions likely hinder formation of the endo transition state thus causing
a decrease in the kcat for the reaction (1).
What prevents Y69 and K32 mutations from displaying substrate and/or cofactor
inhibition? First, no such inhibition is observed in the wild-type enzyme (4). Second,
mutations of both of these residues weaken rather than tighten interactions with NADPH
and DHF ((11), Stinnett et al., manuscript in preparation, Hicks et al., manuscript in
preparation). Third, these residues are located less near the center of the active site (2)
and as such primarily interact with the tail regions of NADPH and DHF (8). As
interligand interactions occur mainly between the pteridine and nicotinamide rings (9),
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Y69 and K32 residues have only an indirect affect on these interactions as they form
contacts with only the tail regions of the molecules (8).
Quad 3 as a Template for Understanding Ligand Binding and Catalysis in R67 DHFR
The Quad 3 construct has proved valuable in gaining insight into ligand binding
and catalysis in R67 DHFR. With this construct, we have been able to control the
number and location of specific mutations within the active site and determine the effects
of these mutations (1). Analyses of the asymmetric Y69F and K32M mutants have
provided support for a model in which residues on one side of the pore, consisting of 2
domains (or monomers in the wild-type enzyme), form contacts with NADPH (Stinnett et
al., manuscript in preparation, Hicks et al., manuscript in preparation). In addition,
results from the Y69F, K32M, and Q67H asymmetric mutant studies support a model
(10) in which catalysis follows a preferred pathway where NADPH interacts with the
enzyme first allowing it to form contacts with the tightest binding site available and
allowing DHF bind to the enzyme-NADPH complex. These studies have also pointed to
the importance of interligand interactions in DHF binding (Stinnett et al., manuscript in
preparation, Hicks et al., manuscript in preparation, (1)). Finally, the Q67H: 1+4 mutant
will likely prove valuable as a template for engineering asymmetric mutations as its
binding affinity towards NADPH is increased in the absence of noticeable DHF and/or
NADPH inhibition (1).
R67 DHFR as a Template for “Evolving” an Enzyme Active Site
Our goal in these research projects has been to determine the mechanisms of
ligand binding and catalysis in R67 DHFR. Our approach has therefore been to perform
site-directed mutagenesis studies that will provide a better understanding of the R67
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DHFR catalyzed reaction. However, these studies have largely focused on understanding
the R67 DHFR reaction and its mechanisms involved in catalysis. How, then, can we
broaden the scope of our research to gain a better understanding of enzyme catalysis in
general using R67 DHFR as a template?
Based on the understanding we have gained regarding the R67 DHFR catalyzed
reaction using several biochemical and biophysical approaches, we propose R67 DHFR
as an ideal template for “evolving” or modifying an enzyme’s active site. Penning and
Jez (12) review the methodologies commonly used to modify or alter enzyme active sites.
In general, there are two approaches to this objective. The first, enzyme redesign, is also
referred to as a “rational” approach as specific mutations are generated in the enzyme
active site which are expected to yield predicted results. For redesigning an active site,
structural information is critical in order to be able to predict the effects of specific
mutations. Two different types of redesign are common, site-directed mutagenesis and
domain switching. In the former, single amino acid residues are mutated while in the
latter, an entire domain of the enzyme is changed. The second approach, directed
evolution, is “irrational” as random mutants of the active sites are generated and selected
on the basis of their having a particular characteristic or function. In contrast to enzyme
redesign, directed evolution does not require extensive structural information since
mutations are added randomly. One common means of directed evolution is phage
display.
Penning and Jez (12) review the use of enzyme redesign and directed evolution to
approach five questions involving ligand binding and catalysis which include the
following. (1) Can an enzyme’s preference for substrate be changed with minimal effects
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on catalytic efficiency using the same mechanism? (2) Can an enzyme be designed to
recognize a cofactor other than its natural cofactor? (3) Can the stereochemistry of an
enzyme’s ligands be altered? (4) Can an enzyme catalyze a reaction other than its natural
reaction? (5) Can a protein be engineered such that it is able to catalyze a reaction? Our
discussion will focus on answering three of the questions using R67 DHFR as question 3
is not straightforward without additional structural information and question 5 is not
applicable. For the purposes of this dissertation, we will focus only on redesign.
The first question that can be approached by enzyme redesign involves
modification of an enzyme’s active site in order to accommodate different substrates
(12). This has been accomplished for lactate dehydrogenase where specificity for
oxaloacetic acid over pyruvate is achieved. In these studies, the active site was
“redesigned” by first comparing the crystal structures for malate and lactate
dehydrogenases in order to predict residues in the substrate binding site of lactate
dehydrogenase that should be mutated for selection of oxaloacetic acid. From these
predictions, three single mutants of lactate dehydrogenase were generated, including
mutations of Q102, D197, and T246 to arginine, asparagine, and glycine, respectively.
For each single mutant, the catalytic efficiency for the alternative ligand, oxaloacetic
acid, was increased. It should be noted that lactate dehydrogenase is capable of using
oxaloacetic acid as a substrate; however, the catalytic efficiency for oxaloacetic acid is
1000 fold less than that for pyruvate. Hence, the active site of lactate dehydrogenase was
“evolved” to recognize oxaloacetic acid as a substrate over pyruvate (12, 13).
Can R67 DHFR be modified such that it recognizes an alternate substrate and
catalyzes its reduction? As a first approach to this objective, Howell and Chopra
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(unpublished data) focused on the PTR1 catalyzed reaction. PTR1 catalyzes the
reduction of biopterin to dihydrobiopterin and dihydrobiopterin to tetrahydrobiopterin
(14-16). Interestingly, however, the enzyme is also capable of reducing folate to
dihydrofolate and dihydrofolate to tetrahydrofolate (14-16). In fact, the enzyme is
proposed to be the cause of unsuccessful attempts at inhibiting DHFR using anti-folate
drugs in clinical settings as the enzyme is able to catalyze the same reaction as DHFR
without being inhibited by anti-folate inhibitors (17-19).
Comparisons of the PTR1 structure to that of R67 DHFR by Howell and Chopra
yielded interesting results. First, both enzymes are active as homotetramers possessing
222 symmetry (2, 14). Similar to the model proposed for R67 DHFR (1, 9, 10), NADPH
comprises a major portion of the substrate binding site for PTR1 (14). In fact, co-crystals
of the complex PTR1-NADPH-MTX (methotrexate, a folate analog) indicate that
"interactions between MTX and PTR1-NADPH occur principally at the pterin end of the
drug and involve direct hydrogen bonds with the cofactor” (14). This compares to NMR
and X-ray crystallography studies for R67 DHFR which suggest that the rings of NADPH
and DHF interact in the pore's center (2, 9). In contrast to R67 DHFR, however, two
active sites are present in PTR1(14).
Based on the similarities between PTR1 and R67 DHFR and their substrates,
Howell and Chopra asked the following question. Is it possible to redesign R67 DHFR to
catalyze the reduction of dihydrobiopterin using NADPH as its cofactor? Preliminary
experiments, performed by S. Chopra using the Quad 3 construct, suggest that R67
DHFR can catalyze the reduction of dihydrobiopterin without the addition of point
mutations. Although this alternate activity is at present rather inefficient, point mutations
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may be added to increase the efficiency of the reaction as was observed for the lactate
dehydrogenase reaction (13). The “hot spot” binding site of R67 DHFR (8) may be
particularly suited for optimizing recognition of alternative ligands.
Another question that can be addressed by enzyme redesign involves modification
of the enzyme’s preference for cofactor, specifically NADPH for NADH (12). Again,
this objective is greatly facilitated by structural information (12) and has been
accomplished for glutathione reductase (20). This enzyme recognizes NADPH as a
cofactor. Comparisons of glutathione reductase from two organisms indicated similar
contacts between the two enzymes and NADPH. Following addition of seven point
mutations, preference for binding the alternate cofactor, NADH, was increased ~18000
fold with respect to NADPH binding. In these experiments, researchers generated
mutations that would not only disfavor recognition of NADPH but would also favor
recognition of NADH (12, 20).
Can cofactor preference for R67 DHFR be modified? R67 DHFR uses NADPH
as a cofactor but can also catalyze the conversion of DHF to THF when NADH is
supplied as the cofactor although the kcat/Km values for NAD(P)H and DHF are decreased
~ 50 fold and ~ 18 fold respectively when NADH is added as the cofactor (7). Since R67
can use NADH as a cofactor, albeit inefficiently, we propose that the active site of R67
DHFR may be “evolved” to select for NADH rather than NADPH.
Salt studies on R67 DHFR suggest that K32 may be involved in an electrostatic
contact with the 2′ phosphate of NADPH. This interaction is likely involved in selection
of NADPH over NADH (7). Therefore, to alter the cofactor preference of R67 DHFR, it
would be necessary to mutate K32 to a residue not capable of forming such interactions
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with the 2′ phosphate. As has been demonstrated previously, this solution is complicated
by the symmetry of R67 DHFR in that mutation of each of the four K32 residues yields
an inactive dimer (7). In addition, generation of asymmetric K32M mutants still provides
at least one wild-type K32 residue with which the cofactor may interact depending on the
location of the mutations (Hicks et al., manuscript in preparation). Therefore, to
accomplish this goal it may be necessary to engineer the active site pore such that
NADPH recognizes only one side of the pore. Specifically, mutation of residues other
than K32 on one side of the pore may be necessary in order to drive DHF binding to that
side of the pore and NADPH binding to the opposite side of the pore. Asymmetric
mutagenesis of K32 residues only on the side of the pore with which NADPH would
interact would then decrease the affinity of NADPH for the enzyme.
Although it may be possible to decrease the affinity of NADPH through
mutagenesis of specific K32 residues, in order to alter cofactor preference, it is necessary
to simultaneously increase affinity for NADH. Penning and Jez (12) maintain that “in
nearly all cases elimination or introduction of basic residues that interact with the 2′phosphate of AMP of NADP(H) often in combination with additional mutations leads to
successful conversion of cofactor preference” (12). However, choosing the “additional
mutations” for R67 DHFR where limited structural information defining cofactor
interactions is available is complex.
Docking studies suggest that, in addition to K32, Y69 may also play a role in
providing contacts for the adenine ribose. Specifically, the ring edge of Y69 is predicted
to form contacts with one of the phosphate oxygens of the adenine ribose (8).
Mutagenesis studies suggest that this interaction may be a charge-dipole interaction that
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is decreased by mutagenesis of the tyrosine to phenylalanine (Stinnett et al., manuscript
in preparation). Could mutation of a Y69 residue(s) to a residue(s) capable of accepting a
hydrogen bond facilitate selection for NADH over NADPH? Again, this mutagenesis
strategy is complicated by the symmetry of the enzyme. Prior to mutating Y69 residues,
it is likely necessary that additional residues be mutated such that one side of the pore
prefers NADPH and the opposite side of the pore prefers DHF. Both Y69 residues on the
side of the pore selecting NADPH could then be mutated to residues capable of accepting
a hydrogen bond. Since the contact is between the ring edge of tyrosine 69 and the
adenine ribose, a smaller hydrogen bond acceptor such as threonine may be capable of
interacting with the 2′ hydroxyl group of NADH while disfavoring interactions with the
2′-phosphate of NADPH. As threonine has a smaller van der Waals volume than
tyrosine, it is however possible that these mutations may disrupt packing interactions.
Additional (or other) mutations may be engineered to select for NADH as more structural
information regarding NADPH binding is obtained using NMR.
A final question that may be approached using redesign of R67 DHFR is
modifying the enzyme to catalyze other reactions (12). One means by which to
accomplish this is by “unmasking” additional activities catalyzed by the enzyme. It has
been suggested that several enzymes are capable of catalyzing other reactions. However,
the efficiency with which they do so is beyond that which is physiologically relevant (12,
21). When these alternate activities are observed, mutations can be engineered into the
enzyme that promote catalysis of an alternate reaction (12). This has been accomplished
for the adenine glycosylase, MutY. Mutation of a single serine residue in this enzyme to
a lysine provides the enzyme with both glycosylase and lyase activities (12, 22).
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Can R67 DHFR be redesigned to catalyze alternate reactions? Interestingly,
NMR studies performed to gain a better understanding of NADPH interactions in the
active site revealed two additional activities catalyzed by the enzyme, a phosphatase
activity and a transhydrogenase activity (23). The first activity was observed as the time
dependent appearance two resonances in the downfield portion of the NMR spectrum
when NADP+ was incubated with the enzyme. These resonances were most consistent
with those of NAD+ suggesting a possible phosphatase activity for R67 DHFR. In
addition, chemical shift data also suggest that R67 DHFR is able to catalyze the transfer
of a hydride ion from NADPH to an analog of NADP+, ADADP+ (3-acetylpyridine
adenine dinucleotide phosphate). The authors propose that K32 is involved in the former
reaction but do not propose residues for involvement in the latter (23). Without more
structural information regarding the contacts between the ligands and the active site,
proposing mutagenesis studies to redesign R67 DHFR to better catalyze these activities is
not straightforward. However, as more structural evidence is obtained via x-ray
crystallography and NMR, the ability to redesign R67 DHFR to better catalyze these
reactions is feasible.
Due to its “hot spot” binding site (8), ability to use NADH as a cofactor (7), and
ability to catalyze alternative reactions (23), we propose R67 DHFR as an ideal enzyme
for redesign of an active site. This is supported by evidence from Matsumura and
Ellington (24) who observed a “non-specific intermediate” with “broadened specificity”
during their attempts to change the activity of the enzyme, beta-glucuronidase. However,
successive rounds of mutagenesis and selection yielded an enzyme with specificity for
the alternate ligand (24). Based on the characteristics of R67 DHFR, it may be possible
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to envision the enzyme as a type of “non-specific intermediate” in that it employs a “hot
spot” binding mechanism (8) and can use NADH as a cofactor (7). Therefore, with the
appropriate mutagenesis strategies, it may be possible to alter the properties of R67
DHFR such that it is able to recognize alternate ligands and catalyze other reactions.
How will these studies be important to the field of enzymology? First, they will
provide a greater understanding of the means by which enzymes catalyze reactions.
Specifically, they will provide more information regarding the types of scaffolds that are
necessary for recognition of alternate substrates and catalysis of new reactions. In
addition, these experiments are important from a pharmaceutical and industrial
perspective as enzymes are redesigned to catalyze novel reactions (12).
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